-
1
-
-
79959524146
-
A haplotype map of the human genome
-
A haplotype map of the human genome. Nature, 2005, 437 (7063), 1299-320.
-
(2005)
Nature
, vol.437
, Issue.7063
, pp. 1299-320
-
-
-
2
-
-
77956331627
-
Integrating common and rare genetic variation in diverse human populations
-
Altshuler, D. M.; Gibbs, R. A.; Peltonen, L.; Dermitzakis, E.; Schaffner, S. F.; Yu, F.; Bonnen, P. E.; de Bakker, P. I.; Deloukas, P.; Gabriel, S. B.; Gwilliam, R.; Hunt, S.; Inouye, M.; Jia, X.; Palotie, A.; Parkin, M.; Whittaker, P.; Chang, K.; Hawes, A.; Lewis, L. R.; Ren, Y.; Wheeler, D.; Muzny, D. M.; Barnes, C.; Darvishi, K.; Hurles, M.; Korn, J. M.; Kristiansson, K.; Lee, C.; McCarrol, S. A.; Nemesh, J.; Keinan, A.; Montgomery, S. B.; Pollack, S.; Price, A. L.; Soranzo, N.; Gonzaga-Jauregui, C.; Anttila, V.; Brodeur, W.; Daly, M. J.; Leslie, S.; McVean, G.; Moutsianas, L.; Nguyen, H.; Zhang, Q.; Ghori, M. J.; McGinnis, R.; McLaren, W.; Takeuchi, F.; Grossman, S. R.; Shlyakhter, I.; Hostetter, E. B.; Sabeti, P. C.; Adebamowo, C. A.; Foster, M. W.; Gordon, D. R.; Licinio, J.; Manca, M. C.; Marshall, P. A.; Matsuda, I.; Ngare, D.; Wang, V. O.; Reddy, D.; Rotimi, C. N.; Royal, C. D.; Sharp, R. R.; Zeng, C.; Brooks, L. D.; McEwen, J. E. Integrating common and rare genetic variation in diverse human populations. Nature, 2010, 467 (7311), 52-58.
-
(2010)
Nature
, vol.467
, Issue.7311
, pp. 52-58
-
-
Altshuler, D.M.1
Gibbs, R.A.2
Peltonen, L.3
Dermitzakis, E.4
Schaffner, S.F.5
Yu, F.6
Bonnen, P.E.7
De Bakker, P.I.8
Deloukas, P.9
Gabriel, S.B.10
Gwilliam, R.11
Hunt, S.12
Inouye, M.13
Jia, X.14
Palotie, A.15
Parkin, M.16
Whittaker, P.17
Chang, K.18
Hawes, A.19
Lewis, L.R.20
Ren, Y.21
Wheeler, D.22
Muzny, D.M.23
Barnes, C.24
Darvishi, K.25
Hurles, M.26
Korn, J.M.27
Kristiansson, K.28
Lee, C.29
McCarrol, S.A.30
Nemesh, J.31
Keinan, A.32
Montgomery, S.B.33
Pollack, S.34
Price, A.L.35
Soranzo, N.36
Gonzaga-Jauregui, C.37
Anttila, V.38
Brodeur, W.39
Daly, M.J.40
Leslie, S.41
McVean, G.42
Moutsianas, L.43
Nguyen, H.44
Zhang, Q.45
Ghori, M.J.46
McGinnis, R.47
McLaren, W.48
Takeuchi, F.49
Grossman, S.R.50
Shlyakhter, I.51
Hostetter, E.B.52
Sabeti, P.C.53
Adebamowo, C.A.54
Foster, M.W.55
Gordon, D.R.56
Licinio, J.57
Manca, M.C.58
Marshall, P.A.59
Matsuda, I.60
Ngare, D.61
Wang, V.O.62
Reddy, D.63
Rotimi, C.N.64
Royal, C.D.65
Sharp, R.R.66
Zeng, C.67
Brooks, L.D.68
McEwen, J.E.69
more..
-
3
-
-
35348983887
-
A second generation human haplotype map of over 3.1 million SNPs
-
DOI 10.1038/nature06258, PII NATURE06258
-
Frazer, K. A.; Ballinger, D. G.; Cox, D. R.; Hinds, D. A.; Stuve, L. L.; Gibbs, R. A.; Belmont, J. W.; Boudreau, A.; Hardenbol, P.; Leal, S. M.; Pasternak, S.; Wheeler, D. A.; Willis, T. D.; Yu, F.; Yang, H.; Zeng, C.; Gao, Y.; Hu, H.; Hu, W.; Li, C.; Lin, W.; Liu, S.; Pan, H.; Tang, X.; Wang, J.; Wang, W.; Yu, J.; Zhang, B.; Zhang, Q.; Zhao, H.; Zhou, J.; Gabriel, S. B.; Barry, R.; Blumenstiel, B.; Camargo, A.; Defelice, M.; Faggart, M.; Goyette, M.; Gupta, S.; Moore, J.; Nguyen, H.; Onofrio, R. C.; Parkin, M.; Roy, J.; Stahl, E.; Winchester, E.; Ziaugra, L.; Altshuler, D.; Shen, Y.; Yao, Z.; Huang, W.; Chu, X.; He, Y.; Jin, L.; Liu, Y.; Sun, W.; Wang, H.; Wang, Y.; Xiong, X.; Xu, L.; Waye, M. M.; Tsui, S. K.; Xue, H.; Wong, J. T.; Galver, L. M.; Fan, J. B.; Gunderson, K.; Murray, S. S.; Oliphant, A. R.; Chee, M. S.; Montpetit, A.; Chagnon, F.; Ferretti, V.; Leboeuf, M.; Olivier, J. F.; Phillips, M. S.; Roumy, S.; Sallee, C.; Verner, A.; Hudson, T. J.; Kwok, P. Y.; Cai, D.; Koboldt, D. C.; Miller, R. D.; Pawlikowska, L.; Taillon- Miller, P.; Xiao, M.; Tsui, L. C.; Mak, W.; Song, Y. Q.; Tam, P. K.; Nakamura, Y.; Kawaguchi, T.; Kitamoto, T.; Morizono, T.; Nagashima, A.; Ohnishi, Y.; Sekine, A.; Tanaka, T.; Tsunoda, T.; Deloukas, P.; Bird, C. P.; Delgado, M.; Dermitzakis, E. T.; Gwilliam, R.; Hunt, S.; Morrison, J.; Powell, D.; Stranger, B. E.; Whittaker, P.; Bentley, D. R.; Daly, M. J.; de Bakker, P. I.; Barrett, J.; Chretien, Y. R.; Maller, J.; McCarroll, S.; Patterson, N.; Pe'er, I.; Price, A.; Purcell, S.; Richter, D. J.; Sabeti, P.; Saxena, R.; Schaffner, S. F.; Sham, P. C.; Varilly, P.; Stein, L. D.; Krishnan, L.; Smith, A. V.; Tello-Ruiz, M. K.; Thorisson, G. A.; Chakravarti, A.; Chen, P. E.; Cutler, D. J.; Kashuk, C. S.; Lin, S.; Abecasis, G. R.; Guan, W.; Li, Y.; Munro, H. M.; Qin, Z. S.; Thomas, D. J.; McVean, G.; Auton, A.; Bottolo, L.; Cardin, N.; Eyheramendy, S.; Freeman, C.; Marchini, J.; Myers, S.; Spencer, C.; Stephens, M.; Donnelly, P.; Cardon, L. R.; Clarke, G.; Evans, D. M.; Morris, A. P.; Weir, B. S.; Mullikin, J. C.; Sherry, S. T.; Feolo, M.; Skol, A.; Zhang, H.; Matsuda, I.; Fukushima, Y.; Macer, D. R.; Suda, E.; Rotimi, C. N.; Adebamowo, C. A.; Ajayi, I.; Aniagwu, T.; Marshall, P. A.; Nkwodimmah, C.; Royal, C. D.; Leppert, M. F.; Dixon, M.; Peiffer, A.; Qiu, R.; Kent, A.; Kato, K.; Niikawa, N.; Adewole, I. F.; Knoppers, B. M.; Foster, M. W.; Clayton, E. W.; Watkin, J.; Muzny, D.; Nazareth, L.; Sodergren, E.; Weinstock, G. M.; Yakub, I.; Birren, B. W.; Wilson, R. K.; Fulton, L. L.; Rogers, J.; Burton, J.; Carter, N. P.; Clee, C. M.; Griffiths, M.; Jones, M. C.; McLay, K.; Plumb, R. W.; Ross, M. T.; Sims, S. K.; Willey, D. L.; Chen, Z.; Han, H.; Kang, L.; Godbout, M.; Wallenburg, J. C.; L'Archeveque, P.; Bellemare, G.; Saeki, K.; An, D.; Fu, H.; Li, Q.; Wang, Z.; Wang, R.; Holden, A. L.; Brooks, L. D.; McEwen, J. E.; Guyer, M. S.; Wang, V. O.; Peterson, J. L.; Shi, M.; Spiegel, J.; Sung, L. M.; Zacharia, L. F.; Collins, F. S.; Kennedy, K.; Jamieson, R.; Stewart, J. A second generation human haplotype map of over 3.1 million SNPs. Nature, 2007, 449 (7164), 851-861. (Pubitemid 47598626)
-
(2007)
Nature
, vol.449
, Issue.7164
, pp. 851-861
-
-
Frazer, K.A.1
Ballinger, D.G.2
Cox, D.R.3
Hinds, D.A.4
Stuve, L.L.5
Gibbs, R.A.6
Belmont, J.W.7
Boudreau, A.8
Hardenbol, P.9
Leal, S.M.10
Pasternak, S.11
Wheeler, D.A.12
Willis, T.D.13
Yu, F.14
Yang, H.15
Zeng, C.16
Gao, Y.17
Hu, H.18
Hu, W.19
Li, C.20
Lin, W.21
Liu, S.22
Pan, H.23
Tang, X.24
Wang, J.25
Wang, W.26
Yu, J.27
Zhang, B.28
Zhang, Q.29
Zhao, H.30
Zhao, H.31
Zhou, J.32
Gabriel, S.B.33
Barry, R.34
Blumenstiel, B.35
Camargo, A.36
Defelice, M.37
Faggart, M.38
Goyette, M.39
Gupta, S.40
Moore, J.41
Nguyen, H.42
Onofrio, R.C.43
Parkin, M.44
Roy, J.45
Stahl, E.46
Winchester, E.47
Ziaugra, L.48
Altshuler, D.49
Shen, Y.50
Yao, Z.51
Huang, W.52
Chu, X.53
He, Y.54
Jin, L.55
Liu, Y.56
Shen, Y.57
Sun, W.58
Wang, H.59
Wang, Y.60
Wang, Y.61
Xiong, X.62
Xu, L.63
Waye, M.M.Y.64
Tsui, S.K.W.65
Xue, H.66
Wong, J.T.-F.67
Galver, L.M.68
Fan, J.-B.69
Gunderson, K.70
Murray, S.S.71
Oliphant, A.R.72
Chee, M.S.73
Montpetit, A.74
Chagnon, F.75
Ferretti, V.76
Leboeuf, M.77
Olivier, J.-F.78
Phillips, M.S.79
Roumy, S.80
Sallee, C.81
Verner, A.82
Hudson, T.J.83
Kwok, P.-Y.84
Cai, D.85
Koboldt, D.C.86
Miller, R.D.87
Pawlikowska, L.88
more..
-
4
-
-
84953723083
-
Pharmacogenomics and personalized medicine: Mapping of future value creation
-
Hu, S. X.; Foster, T.; Kieffaber, A. Pharmacogenomics and personalized medicine: mapping of future value creation. Biotechniques, 2005, 39 (10 Suppl), S1-6.
-
(2005)
Biotechniques
, vol.39
, Issue.10 SUPPL.
-
-
Hu, S.X.1
Foster, T.2
Kieffaber, A.3
-
5
-
-
77954827460
-
The path to personalized medicine
-
Hamburg, M. A.; Collins, F. S. The path to personalized medicine. N. Engl. J. Med., 2010, 363 (4), 301-304.
-
(2010)
N. Engl. J. Med.
, vol.363
, Issue.4
, pp. 301-304
-
-
Hamburg, M.A.1
Collins, F.S.2
-
6
-
-
0035169803
-
Revealing the shared inheritance of all humankind
-
The Human Genome Project
-
Collins, F. S.; Mansoura, M. K. The Human Genome Project. Revealing the shared inheritance of all humankind. Cancer, 2001, 91 (1 Suppl), 221-225.
-
(2001)
Cancer
, vol.91
, Issue.1 SUPPL.
, pp. 221-225
-
-
Collins, F.S.1
Mansoura, M.K.2
-
7
-
-
0035819474
-
Implications of the human genome project for medical science
-
Collins, F. S.; McKusick, V. A. Implications of the Human Genome Project for medical science. JAMA, 2001, 285 (5), 540-544. (Pubitemid 32656320)
-
(2001)
Journal of the American Medical Association
, vol.285
, Issue.5
, pp. 540-544
-
-
Collins, F.S.1
McKusick, V.A.2
-
8
-
-
0037432755
-
The Human Genome Project: Lessons from large-scale biology
-
DOI 10.1126/science.1084564
-
Collins, F. S.; Morgan, M.; Patrinos, A. The Human Genome Project: lessons from large-scale biology. Science, 2003, 300 (5617), 286-290. (Pubitemid 36433711)
-
(2003)
Science
, vol.300
, Issue.5617
, pp. 286-290
-
-
Collins, F.S.1
Morgan, M.2
Patrinos, A.3
-
9
-
-
79955691021
-
-
Submitted for Review
-
Hu, S. X., Trusheim, M. R., Berndt, E. R., Aitken, M. L., Epstein, A. M. Identifying Personalized Medicine Therapeutics and Quantifying Their Utilization. Submitted for Review, 2011.
-
(2011)
Identifying Personalized Medicine Therapeutics and Quantifying Their Utilization
-
-
Hu, S.X.1
Trusheim, M.R.2
Berndt, E.R.3
Aitken, M.L.4
Epstein, A.M.5
-
10
-
-
33947712686
-
Stratified medicine: Strategic and economic implications of combining drugs and clinical biomarkers
-
DOI 10.1038/nrd2251, PII NRD2251
-
Trusheim, M. R.; Berndt, E. R.; Douglas, F. L. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov., 2007, 6 (4), 287-293. (Pubitemid 46505879)
-
(2007)
Nature Reviews Drug Discovery
, vol.6
, Issue.4
, pp. 287-293
-
-
Trusheim, M.R.1
Berndt, E.R.2
Douglas, F.L.3
-
11
-
-
70349386728
-
Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part i
-
Zhou, S. F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin. Pharmacokinet, 2009, 48 (11), 689-723.
-
(2009)
Clin. Pharmacokinet
, vol.48
, Issue.11
, pp. 689-723
-
-
Zhou, S.F.1
-
12
-
-
70449371633
-
Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part II
-
Zhou, S. F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin. Pharmacokinet, 2009, 48 (12), 761-804.
-
(2009)
Clin. Pharmacokinet
, vol.48
, Issue.12
, pp. 761-804
-
-
Zhou, S.F.1
-
13
-
-
78149470864
-
Polymorphisms of human cytochrome P450 2C9 and the functional relevance
-
Zhou, S. F.; Zhou, Z. W.; Huang, M. Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology, 2010, 278 (2), 165-188.
-
(2010)
Toxicology
, vol.278
, Issue.2
, pp. 165-188
-
-
Zhou, S.F.1
Zhou, Z.W.2
Huang, M.3
-
14
-
-
0036394942
-
Clinical significance of the cytochrome P450 2C19 genetic polymorphism
-
Desta, Z.; Zhao, X.; Shin, J. G.; Flockhart, D. A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet, 2002, 41 (12), 913-58. (Pubitemid 35168437)
-
(2002)
Clinical Pharmacokinetics
, vol.41
, Issue.12
, pp. 913-958
-
-
Desta, Z.1
Zhao, X.2
Shin, J.-G.3
Flockhart, D.A.4
-
15
-
-
65949112261
-
Atomoxetine: A review of its use in attention-deficit hyperactivity disorder in children and adolescents
-
Garnock-Jones, K. P.; Keating, G. M. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr. Drugs, 2009, 11 (3), 203-26.
-
(2009)
Paediatr. Drugs
, vol.11
, Issue.3
, pp. 203-26
-
-
Garnock-Jones, K.P.1
Keating, G.M.2
-
16
-
-
42549131532
-
High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients
-
DOI 10.1086/529382
-
Saag, M.; Balu, R.; Phillips, E.; Brachman, P.; Martorell, C.; Burman, W.; Stancil, B.; Mosteller, M.; Brothers, C.; Wannamaker, P.; Hughes, A.; Sutherland-Phillips, D.; Mallal, S.; Shaefer, M. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin. Infect. Dis., 2008, 46 (7), 1111-1118. (Pubitemid 351589880)
-
(2008)
Clinical Infectious Diseases
, vol.46
, Issue.7
, pp. 1111-1118
-
-
Saag, M.S.1
Balu, R.2
Phillips, E.3
Brachman, P.4
Martorell, C.5
Burman, W.6
Stancil, B.7
Mosteller, M.8
Brothers, C.9
Wannamaker, P.10
Hughes, A.11
Sutherland-Phillips, D.12
Mallal, S.13
Shaefer, M.14
-
17
-
-
3142519666
-
Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response
-
DOI 10.1038/sj.mp.4001494
-
Kirchheiner, J.; Nickchen, K.; Bauer, M.; Wong, M. L.; Licinio, J.; Roots, I.; Brockmoller, J. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry, 2004, 9 (5), 442-473. (Pubitemid 38903502)
-
(2004)
Molecular Psychiatry
, vol.9
, Issue.5
, pp. 442-473
-
-
Kirchheiner, J.1
Nickchen, K.2
Bauer, M.3
Wong, M.-L.4
Licinio, J.5
Roots, I.6
Brockmoller, J.7
-
18
-
-
0031949132
-
10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes
-
DOI 10.1016/S0009-9236(98)90040-6
-
Dalen, P.; Dahl, M. L.; Bernal Ruiz, M. L.; Nordin, J.; Bertilsson, L. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin. Pharmacol. Ther., 1998, 63 (4), 444-452. (Pubitemid 28214968)
-
(1998)
Clinical Pharmacology and Therapeutics
, vol.63
, Issue.4
, pp. 444-452
-
-
Dalen, P.1
Dahl, M.-L.2
Ruiz, M.L.B.3
Nordin, J.4
Bertilsson, L.5
-
19
-
-
0029926315
-
Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: Relationship to the CYP2D6 genotype
-
DOI 10.1007/BF02246640
-
Dahl, M. L.; Bertilsson, L.; Nordin, C. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. Psychopharmacology (Berl), 1996, 123 (4), 315-319. (Pubitemid 26075783)
-
(1996)
Psychopharmacology
, vol.123
, Issue.4
, pp. 315-319
-
-
Dahl, M.-L.1
Bertilsson, L.2
Nordin, C.3
-
20
-
-
0034115770
-
Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: Impact of CYP2D6 genotype on the hydroxylation of nortriptyline
-
DOI 10.1097/00004714-200004000-00005
-
Morita, S.; Shimoda, K.; Someya, T.; Yoshimura, Y.; Kamijima, K.; Kato, N. Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline. J. Clin. Psychopharmacol., 2000, 20 (2), 141-149. (Pubitemid 30202355)
-
(2000)
Journal of Clinical Psychopharmacology
, vol.20
, Issue.2
, pp. 141-149
-
-
Morita, S.1
Shimoda, K.2
Someya, T.3
Yoshimura, Y.4
Kamijima, K.5
Kato, N.6
-
21
-
-
12944281041
-
Amitriptyline or not, that is the question: Pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy
-
DOI 10.1373/clinchem.2004.041327
-
Steimer, W.; Zopf, K.; von Amelunxen, S.; Pfeiffer, H.; Bachofer, J.; Popp, J.; Messner, B.; Kissling, W.; Leucht, S. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin. Chem., 2005, 51 (2), 376-385. (Pubitemid 40175808)
-
(2005)
Clinical Chemistry
, vol.51
, Issue.2
, pp. 376-385
-
-
Steimer, W.1
Zopf, K.2
Von Amelunxen, S.3
Pfeiffer, H.4
Bachofer, J.5
Popp, J.6
Messner, B.7
Kissling, W.8
Leucht, S.9
-
22
-
-
0036204756
-
Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs
-
DOI 10.1046/j.0306-5251.2001.01548.x
-
Bertilsson, L.; Dahl, M. L.; Dalen, P.; Al-Shurbaji, A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol., 2002, 53 (2), 111-122. (Pubitemid 34264265)
-
(2002)
British Journal of Clinical Pharmacology
, vol.53
, Issue.2
, pp. 111-122
-
-
Bertilsson, L.1
Dahl, M.-L.2
Dalen, P.3
Al-Shurbaji, A.4
-
23
-
-
0023032092
-
Imipramine demethylation and hydroxylation: Impact of the sparteine oxidation phenotype
-
Brosen, K.; Otton, S. V.; Gram, L. F. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. Clin. Pharmacol. Ther., 1986, 40 (5), 543-549. (Pubitemid 17185089)
-
(1986)
Clinical Pharmacology and Therapeutics
, vol.40
, Issue.5
, pp. 543-549
-
-
Brosen, K.1
Otton, S.V.2
Gram, L.F.3
-
24
-
-
0023139103
-
Hydroxylation of desmethylimipramine: Dependence on the debrisoquin hydroxylation phenotype
-
Spina, E.; Steiner, E.; Ericsson, O.; Sjoqvist, F. Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype. Clin. Pharmacol. Ther., 1987, 41 (3), 314-319. (Pubitemid 17034185)
-
(1987)
Clinical Pharmacology and Therapeutics
, vol.41
, Issue.3
, pp. 314-319
-
-
Spina, E.1
Steiner, E.2
Ericsson, O.3
Sjoqvist, F.4
-
25
-
-
0031028101
-
Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: A prospective study
-
DOI 10.1007/s002280050220
-
Spina, E.; Gitto, C.; Avenoso, A.; Campo, G. M.; Caputi, A. P.; Perucca, E. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur. J. Clin. Pharmacol., 1997, 51 (5), 395-398. (Pubitemid 27055908)
-
(1997)
European Journal of Clinical Pharmacology
, vol.51
, Issue.5
, pp. 395-398
-
-
Spina, E.1
Gitto, C.2
Avenoso, A.3
Campo, G.M.4
Caputi, A.P.5
Perucca, E.6
-
26
-
-
0025011753
-
Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study
-
Sindrup, S. H.; Gram, L. F.; Skjold, T.; Grodum, E.; Brosen, K.; Beck-Nielsen, H. Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind crossover study. Br. J. Clin. Pharmacol., 1990, 30 (5), 683-691. (Pubitemid 20377596)
-
(1990)
British Journal of Clinical Pharmacology
, vol.30
, Issue.5
, pp. 683-691
-
-
Sindrup, S.H.1
Gram, L.F.2
Skjold, T.3
Grodum, E.4
Brosen, K.5
Beck-Nielsen, H.6
-
27
-
-
0025076711
-
Nonlinear kinetics of imipramine in low and medium plasma level ranges
-
Sindrup, S. H.; Brosen, K.; Gram, L. F. Nonlinear kinetics of imipramine in low and medium plasma level ranges. Ther. Drug Monit., 1990, 12 (5), 445-449. (Pubitemid 20314037)
-
(1990)
Therapeutic Drug Monitoring
, vol.12
, Issue.5
, pp. 445-449
-
-
Sindrup, S.H.1
Brosen, K.2
Gram, L.F.3
-
28
-
-
43949120461
-
Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients
-
DOI 10.1038/sj.mp.4002057, PII 4002057
-
Schenk, P. W.; van Fessem, M. A.; Verploegh-Van Rij, S.; Mathot, R. A.; van Gelder, T.; Vulto, A. G.; van Vliet, M.; Lindemans, J.; Bruijn, J. A.; van Schaik, R. H. Association of graded allelespecific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. Mol. Psychiatry., 2008, 13 (6), 597-605. (Pubitemid 351704935)
-
(2008)
Molecular Psychiatry
, vol.13
, Issue.6
, pp. 597-605
-
-
Schenk, P.W.1
Van Fessem, M.A.C.2
Verploegh-Van Rij, S.3
Mathot, R.A.A.4
Van Gelder, T.5
Vulto, A.G.6
Van Vliet, M.7
Lindemans, J.8
Bruijn, J.A.9
Van Schaik, R.H.N.10
-
29
-
-
0036797601
-
Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers
-
DOI 10.1097/00008571-200210000-00010
-
Kirchheiner, J.; Meineke, I.; Muller, G.; Roots, I.; Brockmoller, J. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics, 2002, 12 (7), 571-580. (Pubitemid 35177088)
-
(2002)
Pharmacogenetics
, vol.12
, Issue.7
, pp. 571-580
-
-
Kirchheiner, J.1
Meineke, I.2
Muller, G.3
Roots, I.4
Brockmoller, J.5
-
30
-
-
34548284118
-
A fatal doxepin poisoning associated with a defective CYP2D6 genotype
-
DOI 10.1097/PAF.0b013e3180326701, PII 0000043320070900000018
-
Koski, A.; Ojanpera, I.; Sistonen, J.; Vuori, E.; Sajantila, A. A fatal doxepin poisoning associated with a defective CYP2D6 genotype. Am. J. Forensic Med. Pathol., 2007, 28 (3), 259-261. (Pubitemid 47329748)
-
(2007)
American Journal of Forensic Medicine and Pathology
, vol.28
, Issue.3
, pp. 259-261
-
-
Koski, A.1
Ojanpera, I.2
Sistonen, J.3
Vuori, E.4
Sajantila, A.5
-
31
-
-
29544449443
-
Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19
-
DOI 10.1176/appi.psy.47.1.75
-
de Leon, J.; Armstrong, S. C.; Cozza, K. L. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics, 2006, 47 (1), 75-85. (Pubitemid 43017126)
-
(2006)
Psychosomatics
, vol.47
, Issue.1
, pp. 75-85
-
-
De Leon, J.1
Armstrong, S.C.2
Cozza, K.L.3
-
32
-
-
84921430617
-
SSRIs versus other antidepressants for depressive disorder
-
Geddes, J. R.; Freemantle, N.; Mason, J.; Eccles, M. P.; Boynton, J. SSRIs versus other antidepressants for depressive disorder. Cochrane Database Syst. Rev., 2000, (2), CD001851.
-
(2000)
Cochrane Database Syst. Rev
, Issue.2
-
-
Geddes, J.R.1
Freemantle, N.2
Mason, J.3
Eccles, M.P.4
Boynton, J.5
-
33
-
-
0141505009
-
Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes
-
DOI 10.1046/j.1365-2125.2003.01874.x
-
Herrlin, K.; Yasui-Furukori, N.; Tybring, G.; Widen, J.; Gustafsson, L. L.; Bertilsson, L. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br. J. Clin. Pharmacol., 2003, 56 (4), 415-421. (Pubitemid 37188136)
-
(2003)
British Journal of Clinical Pharmacology
, vol.56
, Issue.4
, pp. 415-421
-
-
Herrlin, K.1
Yasui-Furukori, N.2
Tybring, G.3
Widen, J.4
Gustafsson, L.L.5
Bertilsson, L.6
-
34
-
-
0029827303
-
The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin
-
Hamelin, B. A.; Turgeon, J.; Vallee, F.; Belanger, P. M.; Paquet, F.; LeBel, M. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin. Pharmacol. Ther., 1996, 60 (5), 512-521. (Pubitemid 26414087)
-
(1996)
Clinical Pharmacology and Therapeutics
, vol.60
, Issue.5
, pp. 512-521
-
-
Hamelin, B.A.1
Turgeon, J.2
Vallee, F.3
Belanger, P.-M.4
Paquet, F.5
LeBel, M.6
-
35
-
-
0026576928
-
Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism
-
Sindrup, S. H.; Brosen, K.; Gram, L. F. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin. Pharmacol. Ther., 1992, 51 (3), 288-295.
-
(1992)
Clin. Pharmacol. Ther
, vol.51
, Issue.3
, pp. 288-295
-
-
Sindrup, S.H.1
Brosen, K.2
Gram, L.F.3
-
36
-
-
0032891488
-
The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine
-
Fjordside, L.; Jeppesen, U.; Eap, C. B.; Powell, K.; Baumann, P.; Brosen, K. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Pharmacogenetics, 1999, 9 (1), 55-60. (Pubitemid 29176724)
-
(1999)
Pharmacogenetics
, vol.9
, Issue.1
, pp. 55-60
-
-
Fjordsid, L.1
Jeppesen, U.2
Eap, C.B.3
Powell, K.4
Baumann, P.5
Brosen, K.6
-
37
-
-
0032849017
-
Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers [2]
-
DOI 10.1097/00004714-199910000-00014
-
Ozdemir, V.; Tyndale, R. F.; Reed, K.; Herrmann, N.; Sellers, E. M.; Kalow, W.; Naranjo, C. A. Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers. J. Clin. Psychopharmacol., 1999, 19 (5), 472-475. (Pubitemid 29451514)
-
(1999)
Journal of Clinical Psychopharmacology
, vol.19
, Issue.5
, pp. 472-475
-
-
Ozdemir, V.1
Tyndale, R.F.2
Reed, K.3
Herrmann, N.4
Sellers, E.M.5
Kalow, W.6
Naranjo, C.A.7
-
38
-
-
67650783189
-
Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions
-
Thomas, K. L.; Ellingrod, V. L. Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions. Pharmacotherapy, 2009, 29 (7), 822-831.
-
(2009)
Pharmacotherapy
, vol.29
, Issue.7
, pp. 822-831
-
-
Thomas, K.L.1
Ellingrod, V.L.2
-
39
-
-
37349093041
-
Testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors
-
Recommendations from the EGAPP Working Group
-
Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genetics in Medicine, 2007, 9 (12), 819-825.
-
(2007)
Genetics in Medicine
, vol.9
, Issue.12
, pp. 819-825
-
-
-
40
-
-
25144456112
-
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
-
DOI 10.1056/NEJMoa051688
-
Lieberman, J. A.; Stroup, T. S.; McEvoy, J. P.; Swartz, M. S.; Rosenheck, R. A.; Perkins, D. O.; Keefe, R. S.; Davis, S. M.; Davis, C. E.; Lebowitz, B. D.; Severe, J.; Hsiao, J. K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med., 2005, 353 (12), 1209-1223. (Pubitemid 41345943)
-
(2005)
New England Journal of Medicine
, vol.353
, Issue.12
, pp. 1209-1223
-
-
Lieberman, J.A.1
Scott Stroup, T.2
McEvoy, J.P.3
Swartz, M.S.4
Rosenheck, R.A.5
Perkins, D.O.6
Keefe, R.S.E.7
Davis, S.M.8
Davis, C.E.9
Lebowitz, B.D.10
Severe, J.11
Hsiao, J.K.12
-
41
-
-
0032572599
-
Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics
-
DOI 10.1016/S0920-9964(98)00018-8, PII S0920996498000188
-
Ohmori, O.; Suzuki, T.; Kojima, H.; Shinkai, T.; Terao, T.; Mita, T.; Abe, K. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr. Res., 1998, 32 (2), 107-113. (Pubitemid 28364716)
-
(1998)
Schizophrenia Research
, vol.32
, Issue.2
, pp. 107-113
-
-
Ohmori, O.1
Suzuki, T.2
Kojima, H.3
Shinkai, T.4
Terao, T.5
Mita, T.6
Abe, K.7
-
42
-
-
0035189653
-
Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients
-
Lam, L. C.; Garcia-Barcelo, M. M.; Ungvari, G. S.; Tang, W. K.; Lam, V. K.; Kwong, S. L.; Lau, B. S.; Kwong, P. P.; Waye, M. M.; Chiu, H. F. Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients. Pharmacopsychiatry, 2001, 34 (6), 238-241. (Pubitemid 33086857)
-
(2001)
Pharmacopsychiatry
, vol.34
, Issue.6
, pp. 238-241
-
-
Lam, L.C.W.1
Garcia-Barcelo, M.M.2
Ungvari, G.S.3
Tang, W.K.4
Lam, V.K.L.5
Kwong, S.L.6
Lau, B.S.T.7
Kwong, P.P.K.8
Waye, M.M.Y.9
Chiu, H.F.K.10
-
43
-
-
2342562985
-
Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients
-
Liou, Y. J.; Wang, Y. C.; Bai, Y. M.; Lin, C. C.; Yu, S. C.; Liao, D. L.; Lin, M. W.; Chen, J. Y.; Lai, I. C. Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology, 2004, 49 (4), 167-73.
-
(2004)
Neuropsychobiology
, vol.49
, Issue.4
, pp. 167-73
-
-
Liou, Y.J.1
Wang, Y.C.2
Bai, Y.M.3
Lin, C.C.4
Yu, S.C.5
Liao, D.L.6
Lin, M.W.7
Chen, J.Y.8
Lai, I.C.9
-
44
-
-
12244299890
-
Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics
-
DOI 10.1038/sj.tpj.6500138
-
Nikoloff, D.; Shim, J. C.; Fairchild, M.; Patten, N.; Fijal, B. A.; Koch, W. H.; MacPherson, A.; Flockhart, D.; Yoon, Y. R.; Yoon, J. S.; Kim, Y. H.; Shin, J. G. Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics. Pharmacogenomics J., 2002, 2 (6), 400-407. (Pubitemid 36175802)
-
(2002)
Pharmacogenomics Journal
, vol.2
, Issue.6
, pp. 400-407
-
-
Nikoloff, D.1
Shim, J.-C.2
Fairchild, M.3
Patten, N.4
Fijal, B.A.5
Koch, W.H.6
MacPherson, A.7
Flockhart, D.8
Yoon, Y.-R.9
Yoon, J.-S.10
Kim, Y.-H.11
Shin, J.-G.12
-
45
-
-
0032572604
-
Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia
-
DOI 10.1016/S0920-9964(98)00038-3, PII S0920996498000383
-
Kapitany, T.; Meszaros, K.; Lenzinger, E.; Schindler, S. D.; Barnas, C.; Fuchs, K.; Sieghart, W.; Aschauer, H. N.; Kasper, S. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr. Res., 1998, 32 (2), 101-106 (Pubitemid 28364715)
-
(1998)
Schizophrenia Research
, vol.32
, Issue.2
, pp. 101-106
-
-
Kapitany, T.1
Meszaros, K.2
Lenzinger, E.3
Schindler, S.D.4
Barnas, C.5
Fuchs, K.6
Sieghart, W.7
Aschauer, H.N.8
Kasper, S.9
-
46
-
-
0036844154
-
Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6
-
Ellingrod, V. L.; Schultz, S. K.; Arndt, S. Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6. Pharmacotherapy, 2002, 22 (11), 1416-1419. (Pubitemid 35266377)
-
(2002)
Pharmacotherapy
, vol.22
, Issue.11
, pp. 1416-1419
-
-
Ellingrod, V.L.1
Schultz, S.K.2
Arndt, S.3
-
47
-
-
17644423416
-
CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: A meta-analysis
-
Patsopoulos, N. A.; Ntzani, E. E.; Zintzaras, E.; Ioannidis, J. P. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenet. Genomics, 2005, 15 (3), 151-158. (Pubitemid 40569901)
-
(2005)
Pharmacogenetics and Genomics
, vol.15
, Issue.3
, pp. 151-158
-
-
Patsopoulos, N.A.1
Ntzani, E.E.2
Zintzaras, E.3
Ioannidis, J.P.A.4
-
48
-
-
2642572803
-
Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1
-
DOI 10.1002/humu.20039
-
Neville, M. J.; Johnstone, E. C.; Walton, R. T. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum. Mutat., 2004, 23 (6), 540-545. (Pubitemid 38720604)
-
(2004)
Human Mutation
, vol.23
, Issue.6
, pp. 540-545
-
-
Neville, M.J.1
Johnstone, E.C.2
Walton, R.T.3
-
49
-
-
9844233161
-
D2 dopamine receptor gene (DRD2) Taq 1 A polymorphism: Reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele
-
Thompson, J.; Thomas, N.; Singleton, A.; Piggott, M.; Lloyd, S.; Perry, E. K.; Morris, C. M.; Perry, R. H.; Ferrier, I. N.; Court, J. A. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics, 1997, 7 (6), 479-484. (Pubitemid 27517576)
-
(1997)
Pharmacogenetics
, vol.7
, Issue.6
, pp. 479-484
-
-
Thompson, J.1
Thomas, N.2
Singleton, A.3
Piggott, M.4
Lloyd, S.5
Perry, E.K.6
Morris, C.M.7
Perry, R.H.8
Ferrier, I.N.9
Court, J.A.10
-
50
-
-
0031752522
-
2 receptor availability in healthy volunteers
-
Pohjalainen, T.; Rinne, J. O.; Nagren, K.; Lehikoinen, P.; Anttila, K.; Syvalahti, E. K.; Hietala, J. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol. Psychiatry, 1998, 3 (3), 256-260. (Pubitemid 28266335)
-
(1998)
Molecular Psychiatry
, vol.3
, Issue.3
, pp. 256-260
-
-
Pohjalainen, T.1
Rinne, J.O.2
Nagren, K.3
Lehikoinen, P.4
Anttila, K.5
Syvalahti, E.K.G.6
Hietala, J.7
-
51
-
-
0030598907
-
3 receptor with the Semliki Forest virus system
-
DOI 10.1006/bbrc.1996.1296
-
Lundstrom, K.; Turpin, M. P. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem. Biophys. Res. Commun., 1996, 225 (3), 1068-1072. (Pubitemid 26319228)
-
(1996)
Biochemical and Biophysical Research Communications
, vol.225
, Issue.3
, pp. 1068-1072
-
-
Lundstrom, K.1
Turpin, M.P.2
-
52
-
-
33746043780
-
3 receptor is associated with risk and age-at-onset of essential tremor
-
DOI 10.1073/pnas.0508189103
-
Jeanneteau, F.; Funalot, B.; Jankovic, J.; Deng, H.; Lagarde, J. P.; Lucotte, G.; Sokoloff, P. A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc. Natl. Acad. Sci. U S A, 2006, 103 (28), 10753-10758. (Pubitemid 44078048)
-
(2006)
Proceedings of the National Academy of Sciences of the United States of America
, vol.103
, Issue.28
, pp. 10753-10758
-
-
Jeanneteau, F.1
Funalot, B.2
Jankovic, J.3
Deng, H.4
Lagarde, J.-P.5
Lucotte, G.6
Sokoloff, P.7
-
53
-
-
0032739348
-
Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients
-
Scharfetter, J.; Chaudhry, H. R.; Hornik, K.; Fuchs, K.; Sieghart, W.; Kasper, S.; Aschauer, H. N. Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakastani patients. Eur. Neuropsychopharmacol., 1999, 10 (1), 17-20.
-
(1999)
Eur. Neuropsychopharmacol
, vol.10
, Issue.1
, pp. 17-20
-
-
Scharfetter, J.1
Chaudhry, H.R.2
Hornik, K.3
Fuchs, K.4
Sieghart, W.5
Kasper, S.6
Aschauer, H.N.7
-
54
-
-
12344260363
-
Dopamine D3 receptor Ser9Gly polymorphism and risperidone response
-
Lane, H. Y.; Hsu, S. K.; Liu, Y. C.; Chang, Y. C.; Huang, C. H.; Chang, W. H. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. J. Clin. Psychopharmacol., 2005, 25 (1), 6-11.
-
(2005)
J. Clin. Psychopharmacol
, vol.25
, Issue.1
, pp. 6-11
-
-
Lane, H.Y.1
Hsu, S.K.2
Liu, Y.C.3
Chang, Y.C.4
Huang, C.H.5
Chang, W.H.6
-
55
-
-
0030975438
-
Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia
-
Chen, C. H.; Wei, F. C.; Koong, F. J.; Hsiao, K. J. Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol. Psychiatry, 1997, 41 (7), 827-829.
-
(1997)
Biol. Psychiatry
, vol.41
, Issue.7
, pp. 827-829
-
-
Chen, C.H.1
Wei, F.C.2
Koong, F.J.3
Hsiao, K.J.4
-
56
-
-
33747441496
-
The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia
-
Liou, Y. J.; Lai, I. C.; Liao, D. L.; Chen, J. Y.; Lin, C. C.; Lin, C. Y.; Chen, C. M.; Bai, Y. M.; Chen, T. T.; Wang, Y. C. The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia. Schizophr. Res., 2006, 86 (1-3), 323-325.
-
(2006)
Schizophr. Res
, vol.86
, Issue.1-3
, pp. 323-325
-
-
Liou, Y.J.1
Lai, I.C.2
Liao, D.L.3
Chen, J.Y.4
Lin, C.C.5
Lin, C.Y.6
Chen, C.M.7
Bai, Y.M.8
Chen, T.T.9
Wang, Y.C.10
-
57
-
-
36149001724
-
Support for an association of the C939T polymorphism in the human DRD2 gene with tardive dyskinesia in schizophrenia
-
Mo, G. H.; Lai, I. C.; Wang, Y. C.; Chen, J. Y.; Lin, C. Y.; Chen, T. T.; Chen, M. L.; Liou, Y. J.; Liao, D. L.; Bai, Y. M.; Lin, C. C. Support for an association of the C939T polymorphism in the human DRD2 gene with tardive dyskinesia in schizophrenia. Schizophr. Res., 2007, 97 (1-3), 302-304.
-
(2007)
Schizophr. Res
, vol.97
, Issue.1-3
, pp. 302-304
-
-
Mo, G.H.1
Lai, I.C.2
Wang, Y.C.3
Chen, J.Y.4
Lin, C.Y.5
Chen, T.T.6
Chen, M.L.7
Liou, Y.J.8
Liao, D.L.9
Bai, Y.M.10
Lin, C.C.11
-
58
-
-
34548317252
-
2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients [1]
-
DOI 10.1038/sj.mp.4002023, PII 4002023
-
Zai, C. C.; De Luca, V.; Hwang, R. W.; Voineskos, A.; Muller, D. J.; Remington, G.; Kennedy, J. L. Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Mol. Psychiatry, 2007, 12 (9), 794-795. (Pubitemid 47347796)
-
(2007)
Molecular Psychiatry
, vol.12
, Issue.9
, pp. 794-795
-
-
Zai, C.C.1
De Luca, V.2
Hwang, R.W.3
Voineskos, A.4
Muller, D.J.5
Remington, G.6
Kennedy, J.L.7
-
59
-
-
42349094914
-
Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: A meta-analysis of pharmacogenetic interactions
-
DOI 10.1038/sj.mp.4002142, PII 4002142
-
Bakker, P. R.; van Harten, P. N.; van Os, J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Molecular Psychiatry, 2008, 13 (5), 544-556. (Pubitemid 351556033)
-
(2008)
Molecular Psychiatry
, vol.13
, Issue.5
, pp. 544-556
-
-
Bakker, P.R.1
Van Harten, P.N.2
Van Os, J.3
-
60
-
-
75749148791
-
Pharmacogenetics of antipsychoticinduced side effects
-
Lencz, T.; Malhotra, A. K. Pharmacogenetics of antipsychoticinduced side effects. Dialogues Clin. Neurosci., 2009, 11 (4), 405-415
-
(2009)
Dialogues Clin. Neurosci
, vol.11
, Issue.4
, pp. 405-415
-
-
Lencz, T.1
Malhotra, A.K.2
-
61
-
-
0030903368
-
Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients
-
Steen, V. M.; Lovlie, R.; MacEwan, T.; McCreadie, R. G. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol. Psychiatry, 1997, 2 (2), 139-145. (Pubitemid 27166033)
-
(1997)
Molecular Psychiatry
, vol.2
, Issue.2
, pp. 139-145
-
-
Steen, V.M.1
Lovlie, R.2
MacEwan, T.3
McCreadie, R.G.4
-
62
-
-
0033046439
-
Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia
-
Segman, R.; Neeman, T.; Heresco-Levy, U.; Finkel, B.; Karagichev, L.; Schlafman, M.; Dorevitch, A.; Yakir, A.; Lerner, A.; Shelevoy, A.; Lerer, B. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol. Psychiatry, 1999, 4 (3), 247-253. (Pubitemid 29292174)
-
(1999)
Molecular Psychiatry
, vol.4
, Issue.3
, pp. 247-253
-
-
Segman, R.1
Neeman, T.2
Heresco-Levy, U.3
Finkel, B.4
Karagichev, L.5
Schlafman, M.6
Dorevitch, A.7
Yakir, A.8
Lerner, A.9
Shelevoy, A.10
Lerer, B.11
-
63
-
-
0034894948
-
Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients
-
DOI 10.1159/000054924
-
Liao, D. L.; Yeh, Y. C.; Chen, H. M.; Chen, H.; Hong, C. J.; Tsai, S. J. Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology, 2001, 44 (2), 95-98. (Pubitemid 32722308)
-
(2001)
Neuropsychobiology
, vol.44
, Issue.2
, pp. 95-98
-
-
Liao, D.-L.1
Yeh, Y.-C.2
Chen, H.-M.3
Chen, H.4
Hong, C.-J.5
Tsai, S.-J.6
-
64
-
-
0036342556
-
Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics
-
Woo, S. I.; Kim, J. W.; Rha, E.; Han, S. H.; Hahn, K. H.; Park, C. S.; Sohn, J. W. Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics. Psychiatry Clin. Neurosci., 2002, 56 (4), 469-474.
-
(2002)
Psychiatry Clin. Neurosci
, vol.56
, Issue.4
, pp. 469-474
-
-
Woo, S.I.1
Kim, J.W.2
Rha, E.3
Han, S.H.4
Hahn, K.H.5
Park, C.S.6
Sohn, J.W.7
-
65
-
-
22344436588
-
Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype
-
DOI 10.1017/S1461145705005389
-
Lerer, B.; Segman, R. H.; Tan, E.-C.; Basile, V. S.; Cavallaro, R.; Aschauer, H. N.; Strous, R.; Chong, S.-A.; Heresco-Levy, U.; Verga, M.; Scharfetter, J.; Meltzer, H. Y.; Kennedy, J. L.; Macciardi, F. Combined analysis of 635 patients confirms an agerelated association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. The International Journal of Neuropsychopharmacology, 2005, 8 (3), 411-425. (Pubitemid 41002495)
-
(2005)
International Journal of Neuropsychopharmacology
, vol.8
, Issue.3
, pp. 411-425
-
-
Lerer, B.1
Segman, R.H.2
Tan, E.-C.3
Basile, V.S.4
Cavallaro, R.5
Aschauer, H.N.6
Strous, R.7
Chong, S.-A.8
Heresco-Levy, U.9
Verga, M.10
Scharfetter, J.11
Meltzer, H.Y.12
Kennedy, J.L.13
Macciardi, F.14
-
66
-
-
73949158783
-
The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: A metaanalysis
-
Tsai, H. T.; North, K. E.; West, S. L.; Poole, C. The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: a metaanalysis. Am. J. Med. Genet. B. Neuropsychiatr. Genet., 2010, 153B (1), 57-66.
-
(2010)
Am. J. Med. Genet. B. Neuropsychiatr. Genet.
, vol.153 B
, Issue.1
, pp. 57-66
-
-
Tsai, H.T.1
North, K.E.2
West, S.L.3
Poole, C.4
-
67
-
-
34548671643
-
Pharmacogenetic aspects of therapy with cholinesterase inhibitors: The role of CYP2D6 in Alzheimer's disease pharmacogenetics
-
DOI 10.2174/156720507781788846
-
Cacabelos, R.; Llovo, R.; Fraile, C.; Fernandez-Novoa, L. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics. Curr. Alzheimer Res., 2007, 4 (4), 479-500. (Pubitemid 47416643)
-
(2007)
Current Alzheimer Research
, vol.4
, Issue.4
, pp. 479-500
-
-
Cacabelos, R.1
Llovo, R.2
Fraile, C.3
Fernandez-Novoa, L.4
-
68
-
-
84934444326
-
Pharmacogenomics in Alzheimer's disease
-
Cacabelos, R. Pharmacogenomics in Alzheimer's disease. Methods Mol. Biol., 2008, 448, 213-357.
-
(2008)
Methods Mol. Biol
, vol.448
, pp. 213-357
-
-
Cacabelos, R.1
-
69
-
-
33747888854
-
Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients
-
DOI 10.1007/s00228-006-0168-1
-
Varsaldi, F.; Miglio, G.; Scordo, M. G.; Dahl, M.-L.; Villa, L. M.; Biolcati, A.; Lombardi, G. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients. European Journal of Clinical Pharmacology, 2006, 62 (9), 721-726. (Pubitemid 44289502)
-
(2006)
European Journal of Clinical Pharmacology
, vol.62
, Issue.9
, pp. 721-726
-
-
Varsaldi, F.1
Miglio, G.2
Scordo, M.G.3
Dahl, M.-L.4
Villa, L.M.5
Biolcati, A.6
Lombardi, G.7
-
70
-
-
70349565396
-
Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease
-
Pilotto, A.; Franceschi, M.; D'Onofrio, G.; Bizzarro, A.; Mangialasche, F.; Cascavilla, L.; Paris, F.; Matera, M. G.; Daniele, A.; Mecocci, P.; Masullo, C.; Dallapiccola, B.; Seripa, D. Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology, 2009, 73 (10), 761-767.
-
(2009)
Neurology
, vol.73
, Issue.10
, pp. 761-767
-
-
Pilotto, A.1
Franceschi, M.2
D'Onofrio, G.3
Bizzarro, A.4
Mangialasche, F.5
Cascavilla, L.6
Paris, F.7
Matera, M.G.8
Daniele, A.9
Mecocci, P.10
Masullo, C.11
Dallapiccola, B.12
Seripa, D.13
-
71
-
-
79955693311
-
Association of CYP2D6*4 genetic polymorphism on the metabolism of Donepezil with Alzheimer's disease in Indian population
-
Subbiah, V.; Nirmal, S.; Tripathi, M.; Sagar, R. Association of CYP2D6*4 genetic polymorphism on the metabolism of Donepezil with Alzheimer's disease in Indian population. Annals of General Psychiatry, 2010, 9 (Suppl 1), S142.
-
(2010)
Annals of General Psychiatry
, vol.9
, Issue.SUPPL. 1
-
-
Subbiah, V.1
Nirmal, S.2
Tripathi, M.3
Sagar, R.4
-
72
-
-
34548625125
-
Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele
-
DOI 10.1111/j.1365-2125.2007.02912.x
-
Cui, Y. M.; Teng, C. H.; Pan, A. X.; Yuen, E.; Yeo, K. P.; Zhou, Y.; Zhao, X.; Long, A. J.; Bangs, M. E.; Wise, S. D. Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele. Br. J. Clin. Pharmacol., 2007, 64 (4), 445-449. (Pubitemid 47404304)
-
(2007)
British Journal of Clinical Pharmacology
, vol.64
, Issue.4
, pp. 445-449
-
-
Cui, Y.M.1
Teng, C.H.2
Pan, A.X.3
Yuen, E.4
Yeo, K.P.5
Zhou, Y.6
Zhao, X.7
Long, A.J.8
Bangs, M.E.9
Wise, S.D.10
-
73
-
-
33846407239
-
CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD
-
DOI 10.1097/01.chi.0000246056.83791.b6, PII 0000458320070200000013
-
Michelson, D.; Read, H. A.; Ruff, D. D.; Witcher, J.; Zhang, S.; McCracken, J. CYP2D6 and Clinical Response to Atomoxetine in Children and Adolescents With ADHD. Journal of the American Academy of Child & Adolescent Psychiatry, 2007, 46 (2), 242-251. (Pubitemid 46148423)
-
(2007)
Journal of the American Academy of Child and Adolescent Psychiatry
, vol.46
, Issue.2
, pp. 242-251
-
-
Michelson, D.1
Read, H.A.2
Ruff, D.D.3
Witcher, J.4
Zhang, S.5
McCracken, J.6
-
74
-
-
37349000292
-
CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD
-
DOI 10.1016/j.euroneuro.2007.06.002, PII S0924977X07001265
-
Trzepacz, P. T.; Williams, D. W.; Feldman, P. D.; Wrishko, R. E.; Witcher, J. W.; Buitelaar, J. K. CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD. Eur. Neuropsychopharmacol., 2008, 18 (2), 79-86. (Pubitemid 350296843)
-
(2008)
European Neuropsychopharmacology
, vol.18
, Issue.2
, pp. 79-86
-
-
Trzepacz, P.T.1
Williams, D.W.2
Feldman, P.D.3
Wrishko, R.E.4
Witcher, J.W.5
Buitelaar, J.K.6
-
75
-
-
33745049231
-
Severe liver injury after initiating therapy with atomoxetine in two children
-
DOI 10.1016/j.jpeds.2006.01.035, PII S002234760600014X
-
Lim, J. R.; Faught, P. R.; Chalasani, N. P.; Molleston, J. P. Severe liver injury after initiating therapy with atomoxetine in two children. J .Pediatr., 2006, 148 (6), 831-834. (Pubitemid 43870084)
-
(2006)
Journal of Pediatrics
, vol.148
, Issue.6
, pp. 831-834
-
-
Lim, J.R.1
Faught, P.R.2
Chalasani, N.P.3
Molleston, J.P.4
-
76
-
-
33846187164
-
Combined overdose of atomoxetine and methylphenidate in a cytochrome P450 2D6 poor metabolizer [15]
-
DOI 10.1097/JCP.0b013e31802d782c, PII 0000471420070200000032
-
Reimers, A.; Langsetmo, H. K. Combined overdose of atomoxetine and methylphenidate in a cytochrome P450 2D6 poor metabolizer. J. Clin. Psychopharmacol., 2007, 27 (1), 110-111. (Pubitemid 46105787)
-
(2007)
Journal of Clinical Psychopharmacology
, vol.27
, Issue.1
, pp. 110-111
-
-
Reimers, A.1
Langsetmo, H.K.2
-
77
-
-
77952899450
-
Role of Tetrabenazine for Huntington's Disease-Associated Chorea
-
Poon, L. H.; Kang, G. A.; Lee, A. J. Role of Tetrabenazine for Huntington's Disease-Associated Chorea. Annals of Pharmacotherapy, 2010, 44 (6), 1080-1089.
-
(2010)
Annals of Pharmacotherapy
, vol.44
, Issue.6
, pp. 1080-1089
-
-
Poon, L.H.1
Kang, G.A.2
Lee, A.J.3
-
78
-
-
0031029072
-
Long-term effects of tetrabenazine in hyperkinetic movement disorders
-
Jankovic, J.; Beach, J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology, 1997, 48 (2), 358-362. (Pubitemid 27087603)
-
(1997)
Neurology
, vol.48
, Issue.2
, pp. 358-362
-
-
Jankovic, J.1
Beach, J.2
-
79
-
-
34948839971
-
HLA-B*1502-bound peptides: Implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome
-
Yang, C. W.; Hung, S. I.; Juo, C. G.; Lin, Y. P.; Fang, W. H.; Lu, I. H.; Chen, S. T.; Chen, Y. T. HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome. J. Allergy Clin. Immunol., 2007, 120 (4), 870-877.
-
(2007)
J. Allergy Clin. Immunol
, vol.120
, Issue.4
, pp. 870-877
-
-
Yang, C.W.1
Hung, S.I.2
Juo, C.G.3
Lin, Y.P.4
Fang, W.H.5
Lu, I.H.6
Chen, S.T.7
Chen, Y.T.8
-
80
-
-
1842784823
-
Medical genetics: A marker for Stevens-Johnson syndrome
-
Chung, W. H.; Hung, S. I.; Hong, H. S.; Hsih, M. S.; Yang, L. C.; Ho, H. C.; Wu, J. Y.; Chen, Y. T. Medical genetics: a marker for Stevens-Johnson syndrome. Nature, 2004, 428 (6982), 486.
-
(2004)
Nature
, vol.428
, Issue.6982
, pp. 486
-
-
Chung, W.H.1
Hung, S.I.2
Hong, H.S.3
Hsih, M.S.4
Yang, L.C.5
Ho, H.C.6
Wu, J.Y.7
Chen, Y.T.8
-
81
-
-
33645082244
-
Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions
-
Hung, S. I.; Chung, W. H.; Jee, S. H.; Chen, W. C.; Chang, Y. T.; Lee, W. R.; Hu, S. L.; Wu, M. T.; Chen, G. S.; Wong, T. W.; Hsiao, P. F.; Chen, W. H.; Shih, H. Y.; Fang, W. H.; Wei, C. Y.; Lou, Y. H.; Huang, Y. L.; Lin, J. J.; Chen, Y. T. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics, 2006, 16 (4), 297-306.
-
(2006)
Pharmacogenet. Genomics
, vol.16
, Issue.4
, pp. 297-306
-
-
Hung, S.I.1
Chung, W.H.2
Jee, S.H.3
Chen, W.C.4
Chang, Y.T.5
Lee, W.R.6
Hu, S.L.7
Wu, M.T.8
Chen, G.S.9
Wong, T.W.10
Hsiao, P.F.11
Chen, W.H.12
Shih, H.Y.13
Fang, W.H.14
Wei, C.Y.15
Lou, Y.H.16
Huang, Y.L.17
Lin, J.J.18
Chen, Y.T.19
-
82
-
-
57449118501
-
Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population
-
Locharernkul, C.; Loplumlert, J.; Limotai, C.; Korkij, W.; Desudchit, T.; Tongkobpetch, S.; Kangwanshiratada, O.; Hirankarn, N.; Suphapeetiporn, K.; Shotelersuk, V. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia, 2008, 49 (12), 2087-2091.
-
(2008)
Epilepsia
, vol.49
, Issue.12
, pp. 2087-2091
-
-
Locharernkul, C.1
Loplumlert, J.2
Limotai, C.3
Korkij, W.4
Desudchit, T.5
Tongkobpetch, S.6
Kangwanshiratada, O.7
Hirankarn, N.8
Suphapeetiporn, K.9
Shotelersuk, V.10
-
83
-
-
75649107833
-
HLA class i markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions
-
Ikeda, H.; Takahashi, Y.; Yamazaki, E.; Fujiwara, T.; Kaniwa, N.; Saito, Y.; Aihara, M.; Kashiwagi, M.; Muramatsu, M. HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia, 2010, 51 (2), 297-300.
-
(2010)
Epilepsia
, vol.51
, Issue.2
, pp. 297-300
-
-
Ikeda, H.1
Takahashi, Y.2
Yamazaki, E.3
Fujiwara, T.4
Kaniwa, N.5
Saito, Y.6
Aihara, M.7
Kashiwagi, M.8
Muramatsu, M.9
-
84
-
-
61549115662
-
HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis
-
Kaniwa, N.; Saito, Y.; Aihara, M.; Matsunaga, K.; Tohkin, M.; Kurose, K.; Sawada, J.; Furuya, H.; Takahashi, Y.; Muramatsu, M.; Kinoshita, S.; Abe, M.; Ikeda, H.; Kashiwagi, M.; Song, Y.; Ueta, M.; Sotozono, C.; Ikezawa, Z.; Hasegawa, R. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics, 2008, 9 (11), 1617-1622.
-
(2008)
Pharmacogenomics
, vol.9
, Issue.11
, pp. 1617-1622
-
-
Kaniwa, N.1
Saito, Y.2
Aihara, M.3
Matsunaga, K.4
Tohkin, M.5
Kurose, K.6
Sawada, J.7
Furuya, H.8
Takahashi, Y.9
Muramatsu, M.10
Kinoshita, S.11
Abe, M.12
Ikeda, H.13
Kashiwagi, M.14
Song, Y.15
Ueta, M.16
Sotozono, C.17
Ikezawa, Z.18
Hasegawa, R.19
-
85
-
-
33646934721
-
A marker for Stevens-Johnson syndrome ...: Ethnicity matters
-
DOI 10.1038/sj.tpj.6500356, PII 6500356
-
Lonjou, C.; Thomas, L.; Borot, N.; Ledger, N.; de Toma, C.; LeLouet, H.; Graf, E.; Schumacher, M.; Hovnanian, A.; Mockenhaupt, M.; Roujeau, J. C. A marker for Stevens-Johnson syndrome ...: ethnicity matters. Pharmacogenomics J., 2006, 6 (4), 265-268. (Pubitemid 44137953)
-
(2006)
Pharmacogenomics Journal
, vol.6
, Issue.4
, pp. 265-268
-
-
Lonjou, C.1
Thomas, L.2
Borot, N.3
Ledger, N.4
De Toma, C.5
LeLouet, H.6
Graf, E.7
Schumacher, M.8
Hovnanian, A.9
Mockenhaupt, M.10
Roujeau, J.-C.11
-
86
-
-
33748987340
-
HLA-B locus in Caucasian patients with carbamazepine hypersensitivity
-
DOI 10.2217/14622416.7.6.813
-
Alfirevic, A.; Jorgensen, A. L.; Williamson, P. R.; Chadwick, D. W.; Park, B. K.; Pirmohamed, M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics, 2006, 7 (6), 813-818. (Pubitemid 44446732)
-
(2006)
Pharmacogenomics
, vol.7
, Issue.6
, pp. 813-818
-
-
Alfirevic, A.1
Jorgensen, A.L.2
Williamson, P.R.3
Chadwick, D.W.4
Park, B.K.5
Pirmohamed, M.6
-
87
-
-
34248589506
-
Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese
-
DOI 10.1111/j.1528-1167.2007.01022.x
-
Man, C. B.; Kwan, P.; Baum, L.; Yu, E.; Lau, K. M.; Cheng, A. S.; Ng, M. H. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia, 2007, 48 (5), 1015-1018. (Pubitemid 46763406)
-
(2007)
Epilepsia
, vol.48
, Issue.5
, pp. 1015-1018
-
-
Man, C.B.L.1
Kwan, P.2
Baum, L.3
Yu, E.4
Lau, K.M.5
Cheng, A.S.H.6
Ng, M.H.L.7
-
88
-
-
67649687833
-
Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype
-
Chen, Y. C.; Chu, C. Y.; Hsiao, C. H. Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype. J. Eur. Acad. Dermatol. Venereol., 2009, 23 (6), 702-703.
-
(2009)
J. Eur. Acad. Dermatol. Venereol
, vol.23
, Issue.6
, pp. 702-703
-
-
Chen, Y.C.1
Chu, C.Y.2
Hsiao, C.H.3
-
89
-
-
78651293949
-
Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population
-
An, D. M.; Wu, X. T.; Hu, F. Y.; Yan, B.; Stefan, H.; Zhou, D. Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population. Epilepsy Res., 2010, 92 (2-3), 226-230.
-
(2010)
Epilepsy Res.
, vol.92
, Issue.2-3
, pp. 226-230
-
-
An, D.M.1
Wu, X.T.2
Hu, F.Y.3
Yan, B.4
Stefan, H.5
Zhou, D.6
-
90
-
-
77949600882
-
Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese
-
Hung, S. I.; Chung, W. H.; Liu, Z. S.; Chen, C. H.; Hsih, M. S.; Hui, R. C.; Chu, C. Y.; Chen, Y. T. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics, 2010, 11 (3), 349-356.
-
(2010)
Pharmacogenomics
, vol.11
, Issue.3
, pp. 349-356
-
-
Hung, S.I.1
Chung, W.H.2
Liu, Z.S.3
Chen, C.H.4
Hsih, M.S.5
Hui, R.C.6
Chu, C.Y.7
Chen, Y.T.8
-
91
-
-
65249085648
-
Oxcarbazepineinduced Stevens-Johnson syndrome: A case report
-
Lin, L. C.; Lai, P. C.; Yang, S. F.; Yang, R. C. Oxcarbazepineinduced Stevens-Johnson syndrome: a case report. Kaohsiung J. Med. Sci., 2009, 25 (2), 82-86.
-
(2009)
Kaohsiung J. Med. Sci
, vol.25
, Issue.2
, pp. 82-86
-
-
Lin, L.C.1
Lai, P.C.2
Yang, S.F.3
Yang, R.C.4
-
92
-
-
70249102418
-
High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotriginetreated patients
-
Kazeem, G. R.; Cox, C.; Aponte, J.; Messenheimer, J.; Brazell, C.; Nelsen, A. C.; Nelson, M. R.; Foot, E. High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotriginetreated patients. Pharmacogenet. Genomics, 2009, 19 (9), 661-665.
-
(2009)
Pharmacogenet. Genomics
, vol.19
, Issue.9
, pp. 661-665
-
-
Kazeem, G.R.1
Cox, C.2
Aponte, J.3
Messenheimer, J.4
Brazell, C.5
Nelsen, A.C.6
Nelson, M.R.7
Foot, E.8
-
93
-
-
0029658591
-
359 allelic variant in the tolbutamide polymorphism
-
Sullivan-Klose, T. H.; Ghanayem, B. I.; Bell, D. A.; Zhang, Z. Y.; Kaminsky, L. S.; Shenfield, G. M.; Miners, J. O.; Birkett, D. J.; Goldstein, J. A. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics, 1996, 6 (4), 341-349. (Pubitemid 26288624)
-
(1996)
Pharmacogenetics
, vol.6
, Issue.4
, pp. 341-349
-
-
Sullivan-Klose, T.H.1
Ghanayem, B.I.2
Bell, D.A.3
Zhang, Z.-Y.4
Kaminsky, L.S.5
Shenfield, G.M.6
Miners, J.O.7
Birkett, D.J.8
Goldstein, J.A.9
-
94
-
-
3543006619
-
Functional impact of CYP2C9*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans
-
DOI 10.1016/j.clpt.2004.04.001, PII S0009923604001250
-
Allabi, A. C.; Gala, J. L.; Horsmans, Y.; Babaoglu, M. O.; Bozkurt, A.; Heusterspreute, M.; Yasar, U. Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clin. Pharmacol. Ther., 2004, 76 (2), 113-118. (Pubitemid 39013401)
-
(2004)
Clinical Pharmacology and Therapeutics
, vol.76
, Issue.2
, pp. 113-118
-
-
Allabi, A.C.1
Gala, J.-L.2
Horsmans, Y.3
Babaoglu, M.O.4
Bozkurt, A.5
Heusterspreute, M.6
Yasar, U.7
-
95
-
-
0035217171
-
Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin
-
DOI 10.1097/00008571-200112000-00008
-
Kidd, R. S.; Curry, T. B.; Gallagher, S.; Edeki, T.; Blaisdell, J.; Goldstein, J. A. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics, 2001, 11 (9), 803-808. (Pubitemid 33151515)
-
(2001)
Pharmacogenetics
, vol.11
, Issue.9
, pp. 803-808
-
-
Kidd, R.S.1
Curry, T.B.2
Gallagher, S.3
Edeki, T.4
Blaisdell, J.5
Goldstein, J.A.6
-
96
-
-
0032891790
-
Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9(*)3 allele
-
Kidd, R. S.; Straughn, A. B.; Meyer, M. C.; Blaisdell, J.; Goldstein, J. A.; Dalton, J. T. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics, 1999, 9 (1), 71-80. (Pubitemid 29176726)
-
(1999)
Pharmacogenetics
, vol.9
, Issue.1
, pp. 71-80
-
-
Kidd, R.S.1
Straughn, A.B.2
Meyer, M.C.3
Blaisdell, J.4
Goldstein, J.A.5
Dalton, J.T.6
-
97
-
-
0032819729
-
Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin
-
DOI 10.1046/j.1365-2125.1999.00012.x
-
Aynacioglu, A. S.; Brockmoller, J.; Bauer, S.; Sachse, C.; Guzelbey, P.; Ongen, Z.; Nacak, M.; Roots, I. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br. J.Clin. Pharmacol., 1999, 48 (3), 409-415. (Pubitemid 29417726)
-
(1999)
British Journal of Clinical Pharmacology
, vol.48
, Issue.3
, pp. 409-415
-
-
Sukru Aynacioglu, A.1
Brockmoller, J.2
Bauer, S.3
Sachse, C.4
Guzelbey, P.5
Ongen, Z.6
Nacak, M.7
Roots, I.8
-
98
-
-
20244368950
-
Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin
-
DOI 10.1073/pnas.0407346102
-
Tate, S. K.; Depondt, C.; Sisodiya, S. M.; Cavalleri, G. L.; Schorge, S.; Soranzo, N.; Thom, M.; Sen, A.; Shorvon, S. D.; Sander, J. W.; Wood, N. W.; Goldstein, D. B. Genetic predictors of the maximum doses patients receive during clinical use of the antiepileptic drugs carbamazepine and phenytoin. Proc. Natl. Acad. Sci. U S A, 2005, 102 (15), 5507-5512. (Pubitemid 40530288)
-
(2005)
Proceedings of the National Academy of Sciences of the United States of America
, vol.102
, Issue.15
, pp. 5507-5512
-
-
Tate, S.K.1
Depondt, C.2
Sisodiya, S.M.3
Cavalleri, G.L.4
Schorge, S.5
Soranzo, N.6
Thom, M.7
Sen, A.8
Shorvon, S.D.9
Sander, J.W.10
Wood, N.W.11
Goldstein, D.B.12
-
99
-
-
0034978572
-
The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement
-
DOI 10.1097/00008571-200106000-00002
-
van der Weide, J.; Steijns, L. S.; van Weelden, M. J.; de Haan, K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics, 2001, 11 (4), 287-291. (Pubitemid 32537401)
-
(2001)
Pharmacogenetics
, vol.11
, Issue.4
, pp. 287-291
-
-
Van der Weide, J.1
Steijns, L.S.W.2
Van Weelden, M.J.M.3
De Haan, K.4
-
100
-
-
2942560855
-
450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions
-
DOI 10.1007/s00228-004-0753-0
-
Lee, A. Y.; Kim, M. J.; Chey, W. Y.; Choi, J.; Kim, B. G. Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoininduced cutaneous adverse drug reactions. Eur. J. Clin. Pharmacol., 2004, 60 (3), 155-159. (Pubitemid 38757125)
-
(2004)
European Journal of Clinical Pharmacology
, vol.60
, Issue.3
, pp. 155-159
-
-
Lee, A.-Y.1
Kim, M.-J.2
Chey, W.-Y.3
Choi, J.4
Kim, B.-G.5
-
101
-
-
66649121223
-
Phenytoin Toxicity Due to Genetic Polymorphism
-
McCluggage, L. K.; Voils, S. A.; Bullock, M. R. Phenytoin Toxicity Due to Genetic Polymorphism. Neurocritical Care, 2008, 10 (2), 222-224.
-
(2008)
Neurocritical Care
, vol.10
, Issue.2
, pp. 222-224
-
-
McCluggage, L.K.1
Voils, S.A.2
Bullock, M.R.3
-
102
-
-
66849132349
-
CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant
-
McDonald, M. G.; Rieder, M. J.; Nakano, M.; Hsia, C. K.; Rettie, A. E. CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. Mol. Pharmacol., 2009, 75 (6), 1337-1346.
-
(2009)
Mol. Pharmacol
, vol.75
, Issue.6
, pp. 1337-1346
-
-
McDonald, M.G.1
Rieder, M.J.2
Nakano, M.3
Hsia, C.K.4
Rettie, A.E.5
-
103
-
-
77951758756
-
Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing
-
Roper, N.; Storer, B.; Bona, R.; Fang, M. Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing. J. Mol. Diagn., 2010, 12 (3), 283-291.
-
(2010)
J. Mol. Diagn.
, vol.12
, Issue.3
, pp. 283-291
-
-
Roper, N.1
Storer, B.2
Bona, R.3
Fang, M.4
-
104
-
-
77953624552
-
Role of warfarin pharmacogenetic testing in clinical practice
-
Tan, G. M.; Wu, E.; Lam, Y. Y.; Yan, B. P. Role of warfarin pharmacogenetic testing in clinical practice. Pharmacogenomics, 2010, 11 (3), 439-448.
-
(2010)
Pharmacogenomics
, vol.11
, Issue.3
, pp. 439-448
-
-
Tan, G.M.1
Wu, E.2
Lam, Y.Y.3
Yan, B.P.4
-
105
-
-
42449136621
-
Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: Comparison with other equations
-
DOI 10.2217/14622416.9.2.169
-
Wu, A. H.; Wang, P.; Smith, A.; Haller, C.; Drake, K.; Linder, M.; Valdes, R., Jr. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics, 2008, 9 (2), 169-178. (Pubitemid 351566941)
-
(2008)
Pharmacogenomics
, vol.9
, Issue.2
, pp. 169-178
-
-
Wu, A.H.B.1
Wang, P.2
Smith, A.3
Haller, C.4
Drake, K.5
Linder, M.6
Valdes Jr., R.7
-
106
-
-
33748787999
-
Pharmacogenetics, drug-metabolizing enzymes, and clinical practice
-
DOI 10.1124/pr.58.3.6
-
Gardiner, S. J.; Begg, E. J. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol. Rev., 2006, 58 (3), 521-590. (Pubitemid 44403684)
-
(2006)
Pharmacological Reviews
, vol.58
, Issue.3
, pp. 521-590
-
-
Gardiner, S.J.1
Begg, E.J.2
-
107
-
-
62349134303
-
Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: A prospective study in Chinese patients
-
Huang, S. W.; Chen, H. S.; Wang, X. Q.; Huang, L.; Xu, D. L.; Hu, X. J.; Huang, Z. H.; He, Y.; Chen, K. M.; Xiang, D. K.; Zou, X. M.; Li, Q.; Ma, L. Q.; Wang, H. F.; Chen, B. L.; Li, L.; Jia, Y. K.; Xu, X. M. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet. Genomics, 2009, 19 (3), 226-234.
-
(2009)
Pharmacogenet. Genomics
, vol.19
, Issue.3
, pp. 226-234
-
-
Huang, S.W.1
Chen, H.S.2
Wang, X.Q.3
Huang, L.4
Xu, D.L.5
Hu, X.J.6
Huang, Z.H.7
He, Y.8
Chen, K.M.9
Xiang, D.K.10
Zou, X.M.11
Li, Q.12
Ma, L.Q.13
Wang, H.F.14
Chen, B.L.15
Li, L.16
Jia, Y.K.17
Xu, X.M.18
-
108
-
-
77952570889
-
Warfarin pharmacogenetics: A single VKORC1 polymorphism is predictive of dose across 3 racial groups
-
Limdi, N. A.; Wadelius, M.; Cavallari, L.; Eriksson, N.; Crawford, D. C.; Lee, M. T.; Chen, C. H.; Motsinger-Reif, A.; Sagreiya, H.; Liu, N.; Wu, A. H.; Gage, B. F.; Jorgensen, A.; Pirmohamed, M.; Shin, J. G.; Suarez-Kurtz, G.; Kimmel, S. E.; Johnson, J. A.; Klein, T. E.; Wagner, M. J. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood, 2010, 115 (18), 3827-3834.
-
(2010)
Blood
, vol.115
, Issue.18
, pp. 3827-3834
-
-
Limdi, N.A.1
Wadelius, M.2
Cavallari, L.3
Eriksson, N.4
Crawford, D.C.5
Lee, M.T.6
Chen, C.H.7
Motsinger-Reif, A.8
Sagreiya, H.9
Liu, N.10
Wu, A.H.11
Gage, B.F.12
Jorgensen, A.13
Pirmohamed, M.14
Shin, J.G.15
Suarez-Kurtz, G.16
Kimmel, S.E.17
Johnson, J.A.18
Klein, T.E.19
Wagner, M.J.20
more..
-
109
-
-
77953745542
-
Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population
-
Lubitz, S. A.; Scott, S. A.; Rothlauf, E. B.; Agarwal, A.; Peter, I.; Doheny, D.; Van Der Zee, S.; Jaremko, M.; Yoo, C.; Desnick, R. J.; Halperin, J. L. Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. J. Thromb. Haemost., 2010, 8 (5), 1018-1026.
-
(2010)
J. Thromb. Haemost.
, vol.8
, Issue.5
, pp. 1018-1026
-
-
Lubitz, S.A.1
Scott, S.A.2
Rothlauf, E.B.3
Agarwal, A.4
Peter, I.5
Doheny, D.6
Van Der Zee, S.7
Jaremko, M.8
Yoo, C.9
Desnick, R.J.10
Halperin, J.L.11
-
110
-
-
34347403221
-
Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes
-
DOI 10.1373/clinchem.2006.078139
-
Zhu, Y.; Shennan, M.; Reynolds, K. K.; Johnson, N. A.; Herrnberger, M. R.; Valdes, R., Jr.; Linder, M. W. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin. Chem., 2007, 53 (7), 1199-1205. (Pubitemid 47020974)
-
(2007)
Clinical Chemistry
, vol.53
, Issue.7
, pp. 1199-1205
-
-
Zhu, Y.1
Shennan, M.2
Reynolds, K.K.3
Johnson, N.A.4
Herrnberger, M.R.5
Valdes Jr., R.6
Linder, M.W.7
-
111
-
-
23044440450
-
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen
-
DOI 10.1182/blood-2005-03-1108
-
Sconce, E. A.; Khan, T. I.; Wynne, H. A.; Avery, P.; Monkhouse, L.; King, B. P.; Wood, P.; Kesteven, P.; Daly, A. K.; Kamali, F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood, 2005, 106 (7), 2329-2333. (Pubitemid 41510803)
-
(2005)
Blood
, vol.106
, Issue.7
, pp. 2329-2333
-
-
Sconce, E.A.1
Khan, T.I.2
Wynne, H.A.3
Avery, P.4
Monkhouse, L.5
King, B.P.6
Wood, P.7
Kesteven, P.8
Daly, A.K.9
Kamali, F.10
-
112
-
-
44049102035
-
Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis
-
DOI 10.1038/sj.tpj.6500458, PII 6500458
-
Kindmark, A.; Jawaid, A.; Harbron, C. G.; Barratt, B. J.; Bengtsson, O. F.; Andersson, T. B.; Carlsson, S.; Cederbrant, K. E.; Gibson, N. J.; Armstrong, M.; Lagerstrom-Fermer, M. E.; Dellsen, A.; Brown, E. M.; Thornton, M.; Dukes, C.; Jenkins, S. C.; Firth, M. A.; Harrod, G. O.; Pinel, T. H.; Billing-Clason, S. M.; Cardon, L. R.; March, R. E. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs ofimmunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J., 2008, 8 (3), 186-195. (Pubitemid 351712643)
-
(2008)
Pharmacogenomics Journal
, vol.8
, Issue.3
, pp. 186-195
-
-
Kindmark, A.1
Jawaid, A.2
Harbron, C.G.3
Barratt, B.J.4
Bengtsson, O.F.5
Andersson, T.B.6
Carlsson, S.7
Cederbrant, K.E.8
Gibson, N.J.9
Armstrong, M.10
Lagerstrom-Fermer, M.E.11
Dellsen, A.12
Brown, E.M.13
Thornton, M.14
Dukes, C.15
Jenkins, S.C.16
Firth, M.A.17
Harrod, G.O.18
Pinel, T.H.19
Billing-Clason, S.M.E.20
Cardon, L.R.21
March, R.E.22
more..
-
113
-
-
33746287448
-
Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with Ximelagatran
-
DOI 10.1080/10915810600683143, PII M78T5084531P3NN0
-
Harenberg, J.; Jorg, I.; Weiss, C. Observations of alanine aminotransferase and aspartate aminotransferase in THRIVE studies treated orally with ximelagatran. Int. J. Toxicol., 2006, 25 (3), 165-169. (Pubitemid 44105293)
-
(2006)
International Journal of Toxicology
, vol.25
, Issue.3
, pp. 165-169
-
-
Harenberg, J.1
Jorg, I.2
Weiss, C.3
-
114
-
-
65449158776
-
Clopidogrel resistance: Pharmacokinetic or pharmacogenetic?
-
Ford, N. F. Clopidogrel resistance: pharmacokinetic or pharmacogenetic? J. Clin. Pharmacol., 2009, 49 (5), 506-512.
-
(2009)
J. Clin. Pharmacol
, vol.49
, Issue.5
, pp. 506-512
-
-
Ford, N.F.1
-
115
-
-
33746659807
-
The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts
-
DOI 10.1073/pnas.0510446103
-
Savi, P.; Zachayus, J. L.; Delesque-Touchard, N.; Labouret, C.; Herve, C.; Uzabiaga, M. F.; Pereillo, J. M.; Culouscou, J. M.; Bono, F.; Ferrara, P.; Herbert, J. M. The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc. Natl. Acad. Sci. U S A, 2006, 103 (29), 11069-11074. (Pubitemid 44148419)
-
(2006)
Proceedings of the National Academy of Sciences of the United States of America
, vol.103
, Issue.29
, pp. 11069-11074
-
-
Savi, P.1
Zachayus, J.-L.2
Delesque-Touchard, N.3
Labouret, C.4
Herve, C.5
Uzabiaga, M.-F.6
Pereillo, J.-M.7
Culouscou, J.-M.8
Bono, F.9
Ferrara, P.10
Herbert, J.-M.11
-
116
-
-
17144370263
-
Resistance to clopidogrel: A review of the evidence
-
DOI 10.1016/j.jacc.2005.01.034
-
Nguyen, T. A.; Diodati, J. G.; Pharand, C. Resistance to clopidogrel: a review of the evidence. J. Am.Coll. Cardiol., 2005, 45 (8), 1157-1164. (Pubitemid 40523131)
-
(2005)
Journal of the American College of Cardiology
, vol.45
, Issue.8
, pp. 1157-1164
-
-
Nguyen, T.A.1
Diodati, J.G.2
Pharand, C.3
-
117
-
-
33749339075
-
Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
-
DOI 10.1182/blood-2006-04-013052
-
Hulot, J. S.; Bura, A.; Villard, E.; Azizi, M.; Remones, V.; Goyenvalle, C.; Aiach, M.; Lechat, P.; Gaussem, P. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood, 2006, 108 (7), 2244-2247. (Pubitemid 44497506)
-
(2006)
Blood
, vol.108
, Issue.7
, pp. 2244-2247
-
-
Hulot, J.-S.1
Bura, A.2
Villard, E.3
Azizi, M.4
Remones, V.5
Goyenvalle, C.6
Aiach, M.7
Lechat, P.8
Gaussem, P.9
-
118
-
-
43049179414
-
Cytochrome P450 2C19 681G>A Polymorphism and High On-Clopidogrel Platelet Reactivity Associated With Adverse 1-Year Clinical Outcome of Elective Percutaneous Coronary Intervention With Drug-Eluting or Bare-Metal Stents
-
DOI 10.1016/j.jacc.2007.12.056, PII S0735109708008656
-
Trenk, D.; Hochholzer, W.; Fromm, M. F.; Chialda, L. E.; Pahl, A.; Valina, C. M.; Stratz, C.; Schmiebusch, P.; Bestehorn, H. P.; Buttner, H. J.; Neumann, F. J. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or
-
(2008)
Journal of the American College of Cardiology
, vol.51
, Issue.20
, pp. 1925-1934
-
-
Trenk, D.1
Hochholzer, W.2
Fromm, M.F.3
Chialda, L.-E.4
Pahl, A.5
Valina, C.M.6
Stratz, C.7
Schmiebusch, P.8
Bestehorn, H.-P.9
Buttner, H.J.10
Neumann, F.-J.11
-
119
-
-
58749094444
-
Cytochrome p-450 polymorphisms and response to clopidogrel
-
Mega, J. L.; Close, S. L.; Wiviott, S. D.; Shen, L.; Hockett, R. D.; Brandt, J. T.; Walker, J. R.; Antman, E. M.; Macias, W.; Braunwald, E.; Sabatine, M. S. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med., 2009, 360 (4), 354-362.
-
(2009)
N. Engl. J. Med
, vol.360
, Issue.4
, pp. 354-362
-
-
Mega, J.L.1
Close, S.L.2
Wiviott, S.D.3
Shen, L.4
Hockett, R.D.5
Brandt, J.T.6
Walker, J.R.7
Antman, E.M.8
MacIas, W.9
Braunwald, E.10
Sabatine, M.S.11
-
120
-
-
58749090547
-
Genetic determinants of response to clopidogrel and cardiovascular events
-
Simon, T.; Verstuyft, C.; Mary-Krause, M.; Quteineh, L.; Drouet, E.; Meneveau, N.; Steg, P. G.; Ferrieres, J.; Danchin, N.; Becquemont, L. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med., 2009, 360 (4), 363-375.
-
(2009)
N. Engl. J. Med
, vol.360
, Issue.4
, pp. 363-375
-
-
Simon, T.1
Verstuyft, C.2
Mary-Krause, M.3
Quteineh, L.4
Drouet, E.5
Meneveau, N.6
Steg, P.G.7
Ferrieres, J.8
Danchin, N.9
Becquemont, L.10
-
121
-
-
69249137029
-
Biological determinants of endocrine resistance in breast cancer
-
Musgrove, E. A.; Sutherland, R. L. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer, 2009, 9 (9), 631-643.
-
(2009)
Nat. Rev. Cancer
, vol.9
, Issue.9
, pp. 631-643
-
-
Musgrove, E.A.1
Sutherland, R.L.2
-
122
-
-
79951901358
-
Avoidance of CYP2D6 inhibitors in patients receiving tamoxifen
-
author reply e586
-
Ferraldeschi, R.; Howell, S. J.; Thompson, A. M.; Newman, W. G. Avoidance of CYP2D6 inhibitors in patients receiving tamoxifen. J. Clin. Oncol., 2010, 28 (29), e584-5; author reply e586.
-
(2010)
J. Clin. Oncol.
, vol.28
, Issue.29
-
-
Ferraldeschi, R.1
Howell, S.J.2
Thompson, A.M.3
Newman, W.G.4
-
123
-
-
77956242845
-
CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: Expanded polymorphism coverage improves risk stratification
-
Schroth, W.; Hamann, U.; Fasching, P. A.; Dauser, S.; Winter, S.; Eichelbaum, M.; Schwab, M.; Brauch, H. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin. Cancer Res, 2010, 16 (17), 4468-4477.
-
(2010)
Clin. Cancer Res
, vol.16
, Issue.17
, pp. 4468-4477
-
-
Schroth, W.1
Hamann, U.2
Fasching, P.A.3
Dauser, S.4
Winter, S.5
Eichelbaum, M.6
Schwab, M.7
Brauch, H.8
-
124
-
-
70349929431
-
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen
-
Schroth, W.; Goetz, M. P.; Hamann, U.; Fasching, P. A.; Schmidt, M.; Winter, S.; Fritz, P.; Simon, W.; Suman, V. J.; Ames, M. M.; Safgren, S. L.; Kuffel, M. J.; Ulmer, H. U.; Bolander, J.; Strick, R.; Beckmann, M. W.; Koelbl, H.; Weinshilboum, R. M.; Ingle, J. N.; Eichelbaum, M.; Schwab, M.; Brauch, H. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA, 2009, 302 (13), 1429-1436.
-
(2009)
JAMA
, vol.302
, Issue.13
, pp. 1429-1436
-
-
Schroth, W.1
Goetz, M.P.2
Hamann, U.3
Fasching, P.A.4
Schmidt, M.5
Winter, S.6
Fritz, P.7
Simon, W.8
Suman, V.J.9
Ames, M.M.10
Safgren, S.L.11
Kuffel, M.J.12
Ulmer, H.U.13
Bolander, J.14
Strick, R.15
Beckmann, M.W.16
Koelbl, H.17
Weinshilboum, R.M.18
Ingle, J.N.19
Eichelbaum, M.20
Schwab, M.21
Brauch, H.22
more..
-
125
-
-
34247893863
-
Combined analysis of genetic polymorphisms in thymidylate synthase uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan
-
Martinez-Balibrea, E.; Manzano, J. L.; Martinez-Cardus, A.; Moran, T.; Cirauqui, B.; Catot, S.; Taron, M.; Abad, A. Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan. Oncol. Rep., 2007, 17 (3), 637-645.
-
(2007)
Oncol. Rep
, vol.17
, Issue.3
, pp. 637-645
-
-
Martinez-Balibrea, E.1
Manzano, J.L.2
Martinez-Cardus, A.3
Moran, T.4
Cirauqui, B.5
Catot, S.6
Taron, M.7
Abad, A.8
-
126
-
-
79151482832
-
Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer
-
Glimelius, B.; Garmo, H.; Berglund, A.; Fredriksson, L. A.; Berglund, M.; Kohnke, H.; Bystrom, P.; Sorbye, H.; Wadelius, M. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J., 2010.
-
(2010)
Pharmacogenomics J.
-
-
Glimelius, B.1
Garmo, H.2
Berglund, A.3
Fredriksson, L.A.4
Berglund, M.5
Kohnke, H.6
Bystrom, P.7
Sorbye, H.8
Wadelius, M.9
-
127
-
-
0034892379
-
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)
-
Mathijssen, R. H.; van Alphen, R. J.; Verweij, J.; Loos, W. J.; Nooter, K.; Stoter, G.; Sparreboom, A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res., 2001, 7 (8), 2182-2194. (Pubitemid 32751614)
-
(2001)
Clinical Cancer Research
, vol.7
, Issue.8
, pp. 2182-2194
-
-
Mathijssen, R.H.J.1
Van Alphen, R.J.2
Verweij, J.3
Loos, W.J.4
Nooter, K.5
Stoter, G.6
Sparreboom, A.7
-
128
-
-
66349133649
-
Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan
-
Cecchin, E.; Innocenti, F.; D'Andrea, M.; Corona, G.; De Mattia, E.; Biason, P.; Buonadonna, A.; Toffoli, G. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J. Clin. Oncol., 2009, 27 (15), 2457-2465.
-
(2009)
J. Clin. Oncol
, vol.27
, Issue.15
, pp. 2457-2465
-
-
Cecchin, E.1
Innocenti, F.2
D'Andrea, M.3
Corona, G.4
De Mattia, E.5
Biason, P.6
Buonadonna, A.7
Toffoli, G.8
-
129
-
-
42449139713
-
UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma
-
Liu, C. Y.; Chen, P. M.; Chiou, T. J.; Liu, J. H.; Lin, J. K.; Lin, T. C.; Chen, W. S.; Jiang, J. K.; Wang, H. S.; Wang, W. S. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer, 2008, 112 (9), 1932-1940.
-
(2008)
Cancer
, vol.112
, Issue.9
, pp. 1932-1940
-
-
Liu, C.Y.1
Chen, P.M.2
Chiou, T.J.3
Liu, J.H.4
Lin, J.K.5
Lin, T.C.6
Chen, W.S.7
Jiang, J.K.8
Wang, H.S.9
Wang, W.S.10
-
130
-
-
74549205743
-
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan
-
van der Bol, J. M.; Mathijssen, R. H.; Creemers, G. J.; Planting, A. S.; Loos, W. J.; Wiemer, E. A.; Friberg, L. E.; Verweij, J.; Sparreboom, A.; de Jong, F. A. A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin. Cancer Res., 2010, 16 (2), 736-742.
-
(2010)
Clin. Cancer Res.
, vol.16
, Issue.2
, pp. 736-742
-
-
Van Der Bol, J.M.1
Mathijssen, R.H.2
Creemers, G.J.3
Planting, A.S.4
Loos, W.J.5
Wiemer, E.A.6
Friberg, L.E.7
Verweij, J.8
Sparreboom, A.9
De Jong, F.A.10
-
131
-
-
77953289476
-
Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: A meta-analysis
-
Hu, Z. Y.; Yu, Q.; Zhao, Y. S. Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis. Eur. J. Cancer, 2010, 46 (10), 1856-1865.
-
(2010)
Eur. J. Cancer
, vol.46
, Issue.10
, pp. 1856-1865
-
-
Hu, Z.Y.1
Yu, Q.2
Zhao, Y.S.3
-
132
-
-
35648936586
-
UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia
-
DOI 10.1038/sj.leu.2404827, PII 2404827
-
Singer, J. B.; Shou, Y.; Giles, F.; Kantarjian, H. M.; Hsu, Y.; Robeva, A. S.; Rae, P.; Weitzman, A.; Meyer, J. M.; Dugan, M.; Ottmann, O. G. UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia, 2007, 21 (11), 2311-2315. (Pubitemid 350019230)
-
(2007)
Leukemia
, vol.21
, Issue.11
, pp. 2311-2315
-
-
Singer, J.B.1
Shou, Y.2
Giles, F.3
Kantarjian, H.M.4
Hsu, Y.5
Robeva, A.S.6
Rae, P.7
Weitzman, A.8
Meyer, J.M.9
Dugan, M.10
Ottmann, O.G.11
-
133
-
-
78651083117
-
The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1
-
Fujita, K.; Sugiyama, M.; Akiyama, Y.; Ando, Y.; Sasaki, Y. The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1. Cancer Chemother. Pharmacol., 2011, 67 (1), 237-241.
-
(2011)
Cancer Chemother. Pharmacol.
, vol.67
, Issue.1
, pp. 237-241
-
-
Fujita, K.1
Sugiyama, M.2
Akiyama, Y.3
Ando, Y.4
Sasaki, Y.5
-
134
-
-
45849107951
-
Clinical pharmacology and pharmacogenetics of thiopurines
-
Sahasranaman, S.; Howard, D.; Roy, S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur. J. Clin. Pharmacol., 2008, 64 (8), 753-767.
-
(2008)
Eur. J. Clin. Pharmacol
, vol.64
, Issue.8
, pp. 753-767
-
-
Sahasranaman, S.1
Howard, D.2
Roy, S.3
-
135
-
-
55349099142
-
A personalized approach to cancer treatment: How biomarkers can help
-
Duffy, M. J.; Crown, J. A personalized approach to cancer treatment: how biomarkers can help. Clin. Chem., 2008, 54 (11), 1770-1779.
-
(2008)
Clin. Chem
, vol.54
, Issue.11
, pp. 1770-1779
-
-
Duffy, M.J.1
Crown, J.2
-
136
-
-
36249017274
-
Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia?
-
DOI 10.1111/j.1365-2710.2007.00858.x
-
Fakhoury, M.; Andreu-Gallien, J.; Mahr, A.; Medard, Y.; Azougagh, S.; Vilmer, E.; Jacqz-Aigrain, E. Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia? J. Clin. Pharm. Ther., 2007, 32 (6), 633-639. (Pubitemid 350135107)
-
(2007)
Journal of Clinical Pharmacy and Therapeutics
, vol.32
, Issue.6
, pp. 633-639
-
-
Fakhoury, M.1
Andreu-Gallien, J.2
Mahr, A.3
Medard, Y.4
Azougagh, S.5
Vilmer, E.6
Jacqz-Aigrain, E.7
-
137
-
-
51649130245
-
Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine
-
Hawwa, A. F.; Millership, J. S.; Collier, P. S.; Vandenbroeck, K.; McCarthy, A.; Dempsey, S.; Cairns, C.; Collins, J.; Rodgers, C.; McElnay, J. C. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br. J. Clin. Pharmacol., 2008, 66 (4), 517-528.
-
(2008)
Br. J. Clin. Pharmacol
, vol.66
, Issue.4
, pp. 517-528
-
-
Hawwa, A.F.1
Millership, J.S.2
Collier, P.S.3
Vandenbroeck, K.4
McCarthy, A.5
Dempsey, S.6
Cairns, C.7
Collins, J.8
Rodgers, C.9
McElnay, J.C.10
-
138
-
-
77953591482
-
Thiopurine S-methyltransferase gene polymorphism and 6-mercaptopurine dose intensity in Indian children with acute lymphoblastic leukemia
-
Kapoor, G.; Sinha, R.; Naithani, R.; Chandgothia, M. Thiopurine S-methyltransferase gene polymorphism and 6-mercaptopurine dose intensity in Indian children with acute lymphoblastic leukemia. Leuk. Res., 2010, 34 (8), 1023-1026.
-
(2010)
Leuk. Res.
, vol.34
, Issue.8
, pp. 1023-1026
-
-
Kapoor, G.1
Sinha, R.2
Naithani, R.3
Chandgothia, M.4
-
139
-
-
78650387508
-
Pazopanib in renal cell carcinoma
-
Ward, J. E.; Stadler, W. M. Pazopanib in renal cell carcinoma. Clin. Cancer Res., 2010, 16 (24), 5923-5927.
-
(2010)
Clin. Cancer Res.
, vol.16
, Issue.24
, pp. 5923-5927
-
-
Ward, J.E.1
Stadler, W.M.2
-
140
-
-
77951666852
-
Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism
-
Xu, C. F.; Reck, B. H.; Xue, Z.; Huang, L.; Baker, K. L.; Chen, M.; Chen, E. P.; Ellens, H. E.; Mooser, V. E.; Cardon, L. R.; Spraggs, C. F.; Pandite, L. Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br. J. Cancer, 2010, 102 (9), 1371-1377.
-
(2010)
Br. J. Cancer
, vol.102
, Issue.9
, pp. 1371-1377
-
-
Xu, C.F.1
Reck, B.H.2
Xue, Z.3
Huang, L.4
Baker, K.L.5
Chen, M.6
Chen, E.P.7
Ellens, H.E.8
Mooser, V.E.9
Cardon, L.R.10
Spraggs, C.F.11
Pandite, L.12
-
141
-
-
77958498524
-
An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors
-
Goh, B. C.; Reddy, N. J.; Dandamudi, U. B.; Laubscher, K. H.; Peckham, T.; Hodge, J. P.; Suttle, A. B.; Arumugham, T.; Xu, Y.; Xu, C. F.; Lager, J.; Dar, M. M.; Lewis, L. D. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors. Clin. Pharmacol. Ther., 2010, 88 (5), 652-659.
-
(2010)
Clin. Pharmacol. Ther.
, vol.88
, Issue.5
, pp. 652-659
-
-
Goh, B.C.1
Reddy, N.J.2
Dandamudi, U.B.3
Laubscher, K.H.4
Peckham, T.5
Hodge, J.P.6
Suttle, A.B.7
Arumugham, T.8
Xu, Y.9
Xu, C.F.10
Lager, J.11
Dar, M.M.12
Lewis, L.D.13
-
142
-
-
37449002083
-
Dihydropyrimidine Dehydrogenase Deficiency (Dpd) in Gi Malignancies: Experience of 4-Years
-
Saif, M. W.; Syrigos, K.; Mehra, R.; Mattison, L. K.; Diasio, R. B. Dihydropyrimidine Dehydrogenase Deficiency (Dpd) in Gi Malignancies: Experience of 4-Years. Pak. J. Med. Sci. Q., 2007, 23 (6), 832-839.
-
(2007)
Pak. J. Med. Sci. Q
, vol.23
, Issue.6
, pp. 832-839
-
-
Saif, M.W.1
Syrigos, K.2
Mehra, R.3
Mattison, L.K.4
Diasio, R.B.5
-
143
-
-
0023187085
-
Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile
-
Heggie, G. D.; Sommadossi, J. P.; Cross, D. S.; Huster, W. J.; Diasio, R. B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res., 1987, 47 (8), 2203-2206. (Pubitemid 17074634)
-
(1987)
Cancer Research
, vol.47
, Issue.8
, pp. 2203-2206
-
-
Heggie, G.D.1
Sommadossi, J.-P.2
Cross, D.S.3
-
144
-
-
1942453306
-
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil
-
DOI 10.1016/j.ejca.2003.12.004, PII S0959804903010694
-
van Kuilenburg, A. B. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur. J. Cancer, 2004, 40 (7), 939-950. (Pubitemid 38496249)
-
(2004)
European Journal of Cancer
, vol.40
, Issue.7
, pp. 939-950
-
-
Van Kuilenburg, A.B.P.1
-
145
-
-
14844303761
-
Capecitabine: A review
-
DOI 10.1016/j.clinthera.2005.01.005
-
Walko, C. M.; Lindley, C. Capecitabine: a review. Clin. Ther., 2005, 27 (1), 23-44. (Pubitemid 40347299)
-
(2005)
Clinical Therapeutics
, vol.27
, Issue.1
, pp. 23-44
-
-
Walko, C.M.1
Lindley, C.2
-
146
-
-
0034901306
-
Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: Frequency of the common IVS14+1G>A mutation causing DPD deficiency
-
van Kuilenburg, A. B.; Muller, E. W.; Haasjes, J.; Meinsma, R.; Zoetekouw, L.; Waterham, H. R.; Baas, F.; Richel, D. J.; vanGennip, A. H. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin. Cancer Res., 2001, 7 (5), 1149-1153. (Pubitemid 32708664)
-
(2001)
Clinical Cancer Research
, vol.7
, Issue.5
, pp. 1149-1153
-
-
Van Kuilenburg, A.B.P.1
Muller, E.W.2
Haasjes, J.3
Meinsma, R.4
Zoetekouw, L.5
Waterham, H.R.6
Baas, F.7
Richel, D.J.8
Van Gennip, A.H.9
-
147
-
-
0034808681
-
Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls
-
Raida, M.; Schwabe, W.; Hausler, P.; Van Kuilenburg, A. B.; Van Gennip, A. H.; Behnke, D.; Hoffken, K. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin. Cancer Res., 2001, 7 (9), 2832-2839. (Pubitemid 32911393)
-
(2001)
Clinical Cancer Research
, vol.7
, Issue.9
, pp. 2832-2839
-
-
Raida, M.1
Schwabe, W.2
Hausler, P.3
Van Kuilenburg, A.B.P.4
Van Gennip, A.H.5
Behnke, D.6
Hoffken, K.7
-
148
-
-
0035074119
-
Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-fluorouracil
-
Yamaguchi, K.; Arai, Y.; Kanda, Y.; Akagi, K. Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-Fluorouracil. Jpn. J. Cancer Res, 2001, 92 (3), 337-342. (Pubitemid 32288297)
-
(2001)
Japanese Journal of Cancer Research
, vol.92
, Issue.3
, pp. 337-342
-
-
Yamaguchi, K.1
Arai, Y.2
Kanda, Y.3
Akagi, K.4
-
149
-
-
33749350447
-
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians
-
DOI 10.1158/1078-0432.CCR-06-0747
-
Mattison, L. K.; Fourie, J.; Desmond, R. A.; Modak, A.; Saif, M. W.; Diasio, R. B. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin. Cancer Res., 2006, 12 (18), 5491-5495. (Pubitemid 44497265)
-
(2006)
Clinical Cancer Research
, vol.12
, Issue.18
, pp. 5491-5495
-
-
Mattison, L.K.1
Fourie, J.2
Desmond, R.A.3
Modak, A.4
Saif, M.W.5
Diasio, R.B.6
-
150
-
-
0036798968
-
High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity
-
DOI 10.1097/00008571-200210000-00007
-
Van Kuilenburg, A. B.; Meinsma, R.; Zoetekouw, L.; Van Gennip, A. H. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5- fluorouracil-associated toxicity. Pharmacogenetics, 2002, 12 (7), 555-558. (Pubitemid 35177085)
-
(2002)
Pharmacogenetics
, vol.12
, Issue.7
, pp. 555-558
-
-
Van Kuilenburg, A.B.P.1
Meinsma, R.2
Zoetekouw, L.3
Van Gennip, A.H.4
-
151
-
-
0034488052
-
Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: Identification of new mutations in the DPD gene
-
van Kuilenburg, A. B.; Haasjes, J.; Richel, D. J.; Zoetekouw, L.; Van Lenthe, H.; De Abreu, R. A.; Maring, J. G.; Vreken, P.; van Gennip, A. H. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5- fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin. Cancer Res., 2000, 6 (12), 4705-4712. (Pubitemid 32110408)
-
(2000)
Clinical Cancer Research
, vol.6
, Issue.12
, pp. 4705-4712
-
-
Van Kuilenburg, A.B.P.1
Haasjes, J.2
Richel, D.J.3
Zoetekouw, L.4
Van Lenthe, H.5
De Abreu, R.A.6
Maring, J.G.7
Vreken, P.8
Van Gennip, A.H.9
-
152
-
-
0035712169
-
Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: The importance of analysis at diagnosis and significance of long-term follow-up
-
Papajik, T.; Jedlickova, K.; Kriegova, E.; Jarosova, M.; Raida, L.; Faber, E.; Hubacek, J.; Vondrakova, J.; Pikalova, Z.; Indrak, K. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up. Neoplasma, 2001, 48 (6), 501-505. (Pubitemid 34132567)
-
(2001)
Neoplasma
, vol.48
, Issue.6
, pp. 501-505
-
-
Papajik, T.1
Jedlickova, K.2
Kriegova, E.3
Jarosova, M.4
Raida, L.5
Faber, E.6
Hubacek, J.7
Vondrakova, J.8
Pikalova, Z.9
Indrak, K.10
-
153
-
-
0034470711
-
Dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil associated toxicity
-
van Kuilenburg, A. B.; Haasjes, J.; Van Lenthe, H.; Zoetekouw, L.; Waterham, H. R.; Vreken, P.; van Gennip, A. H. Dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil associated toxicity. Adv. Exp. Med. Biol., 2000, 486, 251-255. (Pubitemid 32179307)
-
(2000)
Advances in Experimental Medicine and Biology
, vol.486
, pp. 251-255
-
-
Van Kuilenburg, A.B.P.1
Haasjes, J.2
Van Lenthe, H.3
Zoetekouw, L.4
Waterham, H.R.5
Vreken, P.6
Van Gennip, A.H.7
-
154
-
-
33845219798
-
Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance
-
DOI 10.1158/1535-7163.MCT-06-0327
-
Morel, A.; Boisdron-Celle, M.; Fey, L.; Soulie, P.; Craipeau, M. C.; Traore, S.; Gamelin, E. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol. Cancer Ther., 2006, 5 (11), 2895-2904. (Pubitemid 44849017)
-
(2006)
Molecular Cancer Therapeutics
, vol.5
, Issue.11
, pp. 2895-2904
-
-
Morel, A.1
Boisdron-Celle, M.2
Fey, L.3
Soulie, P.4
Craipeau, M.C.5
Traore, S.6
Gamelin, E.7
-
155
-
-
33749356788
-
Pharmacogenetics of capecitabine in advanced breast cancer patients
-
DOI 10.1158/1078-0432.CCR-06-0320
-
Largillier, R.; Etienne-Grimaldi, M. C.; Formento, J. L.; Ciccolini, J.; Nebbia, J. F.; Ginot, A.; Francoual, M.; Renee, N.; Ferrero, J. M.; Foa, C.; Namer, M.; Lacarelle, B.; Milano, G. Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin. Cancer Res., 2006, 12 (18), 5496-5502. (Pubitemid 44497266)
-
(2006)
Clinical Cancer Research
, vol.12
, Issue.18
, pp. 5496-5502
-
-
Largillier, R.1
Etienne-Grimaldi, M.-C.2
Formento, J.-L.3
Ciccolini, J.4
Nebbia, J.-F.5
Ginot, A.6
Francoual, M.7
Renee, N.8
Ferrero, J.-M.9
Foa, C.10
Namer, M.11
Lacarelle, B.12
Milano, G.13
-
156
-
-
70649097093
-
Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas
-
Ragia, G.; Petridis, I.; Tavridou, A.; Christakidis, D.; Manolopoulos, V. G. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics, 2009, 10 (11), 1781-1787.
-
(2009)
Pharmacogenomics
, vol.10
, Issue.11
, pp. 1781-1787
-
-
Ragia, G.1
Petridis, I.2
Tavridou, A.3
Christakidis, D.4
Manolopoulos, V.G.5
-
157
-
-
72949108032
-
Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance
-
Wang, B.; Wang, J.; Huang, S. Q.; Su, H. H.; Zhou, S. F. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. Curr. Drug Metab, 2009, 10 (7), 781-834.
-
(2009)
Curr. Drug Metab
, vol.10
, Issue.7
, pp. 781-834
-
-
Wang, B.1
Wang, J.2
Huang, S.Q.3
Su, H.H.4
Zhou, S.F.5
-
158
-
-
21744439005
-
Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents
-
DOI 10.1111/j.1365-2125.2005.02379.x
-
Holstein, A.; Plaschke, A.; Ptak, M.; Egberts, E. H.; El-Din, J.; Brockmoller, J.; Kirchheiner, J. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br. J. Clin. Pharmacol., 2005, 60 (1), 103-106. (Pubitemid 40942788)
-
(2005)
British Journal of Clinical Pharmacology
, vol.60
, Issue.1
, pp. 103-106
-
-
Holstein, A.1
Plaschke, A.2
Ptak, M.3
Egberts, E.-H.4
El-Din, J.5
Brockmoller, J.6
Kirchheiner, J.7
-
159
-
-
37349064108
-
Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel
-
DOI 10.1016/j.jaad.2007.08.036, PII S0190962207013217
-
Halevy, S.; Ghislain, P. D.; Mockenhaupt, M.; Fagot, J. P.; Bouwes Bavinck, J. N.; Sidoroff, A.; Naldi, L.; Dunant, A.; Viboud, C.; Roujeau, J. C. Allopurinol is the most common cause of Stevens- Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J. Am. Acad. Dermatol., 2008, 58 (1), 25-32. (Pubitemid 350298142)
-
(2008)
Journal of the American Academy of Dermatology
, vol.58
, Issue.1
, pp. 25-32
-
-
Halevy, S.1
Ghislain, P.-D.2
Mockenhaupt, M.3
Fagot, J.-P.4
Bouwes Bavinck, J.N.5
Sidoroff, A.6
Naldi, L.7
Dunant, A.8
Viboud, C.9
Roujeau, J.-C.10
-
160
-
-
44149110334
-
Allopurinol hypersensitivity syndrome: A preventable severe cutaneous adverse reaction?
-
Lee, H. Y.; Ariyasinghe, J. T.; Thirumoorthy, T. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction? Singapore Med. J., 2008, 49 (5), 384-387. (Pubitemid 351716706)
-
(2008)
Singapore Medical Journal
, vol.49
, Issue.5
, pp. 384-387
-
-
Lee, H.Y.1
Ariyasinghe, J.T.N.2
Thirumoorthy, T.3
-
161
-
-
15244349566
-
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
-
DOI 10.1073/pnas.0409500102
-
Hung, S. I.; Chung, W. H.; Liou, L. B.; Chu, C. C.; Lin, M.; Huang, H. P.; Lin, Y. L.; Lan, J. L.; Yang, L. C.; Hong, H. S.; Chen, M. J.; Lai, P. C.; Wu, M. S.; Chu, C. Y.; Wang, K. H.; Chen, C. H.; Fann, C. S.; Wu, J. Y.; Chen, Y. T. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl. Acad. Sci. U S A, 2005, 102 (11), 4134-4139. (Pubitemid 40388568)
-
(2005)
Proceedings of the National Academy of Sciences of the United States of America
, vol.102
, Issue.11
, pp. 4134-4139
-
-
Hung, S.-L.1
Chung, W.-H.2
Liou, L.-B.3
Chu, C.-C.4
Lin, M.5
Huang, H.-P.6
Lin, Y.-L.7
Lan, J.-L.8
Yang, L.-C.9
Hong, H.-S.10
Chen, M.-J.11
Lai, P.-C.12
Wu, M.-S.13
Chu, C.-Y.14
Wang, K.-H.15
Chen, C.-H.16
Fann, C.S.J.17
Wu, J.-Y.18
Chen, Y.-T.19
-
162
-
-
70249122727
-
Strong association between HLA-B*5801 and allopurinolinduced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population
-
Tassaneeyakul, W.; Jantararoungtong, T.; Chen, P.; Lin, P. Y.; Tiamkao, S.; Khunarkornsiri, U.; Chucherd, P.; Konyoung, P.; Vannaprasaht, S.; Choonhakarn, C.; Pisuttimarn, P.; Sangviroon, A. Strong association between HLA-B*5801 and allopurinolinduced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet. Genomics, 2009, 19 (9), 704-709.
-
(2009)
Pharmacogenet. Genomics
, vol.19
, Issue.9
, pp. 704-709
-
-
Tassaneeyakul, W.1
Jantararoungtong, T.2
Chen, P.3
Lin, P.Y.4
Tiamkao, S.5
Khunarkornsiri, U.6
Chucherd, P.7
Konyoung, P.8
Vannaprasaht, S.9
Choonhakarn, C.10
Pisuttimarn, P.11
Sangviroon, A.12
-
163
-
-
34250888038
-
Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: What causes the diversity? [4]
-
DOI 10.1159/000102045
-
Dainichi, T.; Uchi, H.; Moroi, Y.; Furue, M. Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity? Dermatology, 2007, 215 (1), 86-88. (Pubitemid 46976024)
-
(2007)
Dermatology
, vol.215
, Issue.1
, pp. 86-88
-
-
Dainichi, T.1
Uchi, H.2
Moroi, Y.3
Furue, M.4
-
164
-
-
38149108354
-
A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs
-
Lonjou, C.; Borot, N.; Sekula, P.; Ledger, N.; Thomas, L.; Halevy, S.; Naldi, L.; Bouwes-Bavinck, J. N.; Sidoroff, A.; de Toma, C.; Schumacher, M.; Roujeau, J. C.; Hovnanian, A.; Mockenhaupt, M. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet. Genomics, 2008, 18 (2), 99-107.
-
(2008)
Pharmacogenet. Genomics
, vol.18
, Issue.2
, pp. 99-107
-
-
Lonjou, C.1
Borot, N.2
Sekula, P.3
Ledger, N.4
Thomas, L.5
Halevy, S.6
Naldi, L.7
Bouwes-Bavinck, J.N.8
Sidoroff, A.9
De Toma, C.10
Schumacher, M.11
Roujeau, J.C.12
Hovnanian, A.13
Mockenhaupt, M.14
-
165
-
-
41149096014
-
Abacavir hypersensitivity reaction: An update
-
DOI 10.1345/aph.1K522
-
Hughes, C. A.; Foisy, M. M.; Dewhurst, N.; Higgins, N.; Robinson, L.; Kelly, D. V.; Lechelt, K. E. Abacavir hypersensitivity reaction: an update. Ann. Pharmacother., 2008, 42 (3), 387-396. (Pubitemid 351429604)
-
(2008)
Annals of Pharmacotherapy
, vol.42
, Issue.3
, pp. 387-396
-
-
Hughes, C.A.1
Foisy, M.M.2
Dewhurst, N.3
Higgins, N.4
Robinson, L.5
Kelly, D.V.6
Lechelt, K.E.7
-
166
-
-
65549125416
-
Genetic association studies to detect adverse drug reactions: Abacavir hypersensitivity as an example
-
Hughes, A. R.; Brothers, C. H.; Mosteller, M.; Spreen, W. R.; Burns, D. K. Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example. Pharmacogenomics, 2009, 10 (2), 225-233.
-
(2009)
Pharmacogenomics
, vol.10
, Issue.2
, pp. 225-233
-
-
Hughes, A.R.1
Brothers, C.H.2
Mosteller, M.3
Spreen, W.R.4
Burns, D.K.5
-
167
-
-
52149112915
-
Pharmacogenetics of hypersensitivity to abacavir: From PGx hypothesis to confirmation to clinical utility
-
Hughes, A. R.; Spreen, W. R.; Mosteller, M.; Warren, L. L.; Lai, E. H.; Brothers, C. H.; Cox, C.; Nelsen, A. J.; Hughes, S.; Thorborn, D. E.; Stancil, B.; Hetherington, S. V.; Burns, D. K.; Roses, A. D. Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. Pharmacogenomics J., 2008, 8 (6), 365-374.
-
(2008)
Pharmacogenomics J
, vol.8
, Issue.6
, pp. 365-374
-
-
Hughes, A.R.1
Spreen, W.R.2
Mosteller, M.3
Warren, L.L.4
Lai, E.H.5
Brothers, C.H.6
Cox, C.7
Nelsen, A.J.8
Hughes, S.9
Thorborn, D.E.10
Stancil, B.11
Hetherington, S.V.12
Burns, D.K.13
Roses, A.D.14
-
168
-
-
44649104544
-
+ T Cells Provides the Immunogenetic Basis of a Systemic Drug Hypersensitivity
-
DOI 10.1016/j.immuni.2008.04.020, PII S1074761308002422
-
Chessman, D.; Kostenko, L.; Lethborg, T.; Purcell, A. W.; Williamson, N. A.; Chen, Z.; Kjer-Nielsen, L.; Mifsud, N. A.; Tait, B. D.; Holdsworth, R.; Almeida, C. A.; Nolan, D.; Macdonald, W. A.; Archbold, J. K.; Kellerher, A. D.; Marriott, D.; Mallal, S.; Bharadwaj, M.; Rossjohn, J.; McCluskey, J. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity, 2008, 28 (6), 822-832. (Pubitemid 351784513)
-
(2008)
Immunity
, vol.28
, Issue.6
, pp. 822-832
-
-
Chessman, D.1
Kostenko, L.2
Lethborg, T.3
Purcell, A.W.4
Williamson, N.A.5
Chen, Z.6
Kjer-Nielsen, L.7
Mifsud, N.A.8
Tait, B.D.9
Holdsworth, R.10
Almeida, C.A.11
Nolan, D.12
Macdonald, W.A.13
Archbold, J.K.14
Kellerher, A.D.15
Marriott, D.16
Mallal, S.17
Bharadwaj, M.18
Rossjohn, J.19
McCluskey, J.20
more..
-
169
-
-
38449112126
-
Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards
-
Rodriguez-Novoa, S.; Garcia-Gasco, P.; Blanco, F.; Gonzalez- Pardo, G.; Castellares, C.; Moreno, V.; Jimenez-Nacher, I.; Gonzalez-Lahoz, J.; Soriano, V. Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards. AIDS Res. Hum. Retroviruses, 2007, 23 (11), 1374-11376.
-
(2007)
AIDS Res. Hum. Retroviruses
, vol.23
, Issue.11
, pp. 1374-11376
-
-
Rodriguez-Novoa, S.1
Garcia-Gasco, P.2
Blanco, F.3
Gonzalez- Pardo, G.4
Castellares, C.5
Moreno, V.6
Jimenez-Nacher, I.7
Gonzalez-Lahoz, J.8
Soriano, V.9
-
170
-
-
38949196447
-
HLA-B*5701 screening for hypersensitivity to abacavir
-
Mallal, S.; Phillips, E.; Carosi, G.; Molina, J. M.; Workman, C.; Tomazic, J.; Jagel-Guedes, E.; Rugina, S.; Kozyrev, O.; Cid, J. F.; Hay, P.; Nolan, D.; Hughes, S.; Hughes, A.; Ryan, S.; Fitch, N.; Thorborn, D.; Benbow, A. HLA-B*5701 screening for hypersensitivity to abacavir. N .Engl. J. Med., 2008, 358 (6), 568-579.
-
(2008)
N. Engl. J. Med
, vol.358
, Issue.6
, pp. 568-579
-
-
Mallal, S.1
Phillips, E.2
Carosi, G.3
Molina, J.M.4
Workman, C.5
Tomazic, J.6
Jagel-Guedes, E.7
Rugina, S.8
Kozyrev, O.9
Cid, J.F.10
Hay, P.11
Nolan, D.12
Hughes, S.13
Hughes, A.14
Ryan, S.15
Fitch, N.16
Thorborn, D.17
Benbow, A.18
-
171
-
-
12144287198
-
Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant
-
DOI 10.1073/pnas.0307067101
-
Martin, A. M.; Nolan, D.; Gaudieri, S.; Almeida, C. A.; Nolan, R.; James, I.; Carvalho, F.; Phillips, E.; Christiansen, F. T.; Purcell, A. W.; McCluskey, J.; Mallal, S. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl. Acad. Sci. U S A, 2004, 101 (12), 4180-4185. (Pubitemid 38405903)
-
(2004)
Proceedings of the National Academy of Sciences of the United States of America
, vol.101
, Issue.12
, pp. 4180-4185
-
-
Martin, A.M.1
Nolan, D.2
Gaudieri, S.3
Almeida, C.A.4
Nolan, R.5
James, I.6
Carvalho, F.7
Phillips, E.8
Christiansen, F.T.9
Purcell, A.W.10
McCluskey, J.11
Mallal, S.12
-
172
-
-
20144380564
-
HLA-B*5701 typing by sequence-specific amplification: Validation and comparison with sequence-based typing
-
DOI 10.1111/j.1399-0039.2005.00401.x
-
Martin, A. M.; Nolan, D.; Mallal, S. HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing. Tissue Antigens, 2005, 65 (6), 571-574. (Pubitemid 40776308)
-
(2005)
Tissue Antigens
, vol.65
, Issue.6
, pp. 571-574
-
-
Martin, A.M.1
Nolan, D.2
Mallal, S.3
-
173
-
-
36349024340
-
Prospective HLA-B*5701 screening and abacavir hypersensitivity: A single centre experience
-
DOI 10.1097/QAD.0b013e328273bc07, PII 0000203020071130000020
-
Waters, L. J.; Mandalia, S.; Gazzard, B.; Nelson, M. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience. Aids, 2007, 21 (18), 2533-2534. (Pubitemid 350145186)
-
(2007)
AIDS
, vol.21
, Issue.18
, pp. 2533-2534
-
-
Waters, L.J.1
Mandalia, S.2
Gazzard, B.3
Nelson, M.4
-
174
-
-
0037006623
-
Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir
-
DOI 10.1016/S0140-6736(02)07873-X
-
Mallal, S.; Nolan, D.; Witt, C.; Masel, G.; Martin, A. M.; Moore, C.; Sayer, D.; Castley, A.; Mamotte, C.; Maxwell, D.; James, I.; Christiansen, F. T. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reversetranscriptase inhibitor abacavir. Lancet, 2002, 359 (9308), 727-732. (Pubitemid 34215071)
-
(2002)
Lancet
, vol.359
, Issue.9308
, pp. 727-732
-
-
Mallal, S.1
Nolan, D.2
Witt, C.3
Masel, G.4
Martin, A.M.5
Moore, C.6
Sayer, D.7
Castley, A.8
Mamotte, C.9
Maxwell, D.10
James, I.11
Christiansen, F.T.12
-
175
-
-
42449120613
-
Pharmacogenetic information derived from analysis of HLA alleles
-
DOI 10.2217/14622416.9.2.207
-
Gatanaga, H.; Honda, H.; Oka, S. Pharmacogenetic information derived from analysis of HLA alleles. Pharmacogenomics, 2008, 9 (2), 207-214. (Pubitemid 351566944)
-
(2008)
Pharmacogenomics
, vol.9
, Issue.2
, pp. 207-214
-
-
Gatanaga, H.1
Honda, H.2
Oka, S.3
-
176
-
-
17144377479
-
The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART
-
van Leth, F.; Andrews, S.; Grinsztejn, B.; Wilkins, E.; Lazanas, M. K.; Lange, J. M.; Montaner, J. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. Aids, 2005, 19 (5), 463-471. (Pubitemid 40515849)
-
(2005)
AIDS
, vol.19
, Issue.5
, pp. 463-471
-
-
Van Leth, F.1
Andrews, S.2
Grinsztejn, B.3
Wilkins, E.4
Lazanas, M.K.5
Lange, J.M.A.6
Montaner, J.7
-
177
-
-
12144260460
-
Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts
-
Martin, A. M.; Nolan, D.; James, I.; Cameron, P.; Keller, J.; Moore, C.; Phillips, E.; Christiansen, F. T.; Mallal, S. Predisposition to nevirapine hypersensitivity associated with HLADRB1* 0101 and abrogated by low CD4 T-cell counts. Aids, 2005, 19 (1), 97-99. (Pubitemid 40111026)
-
(2005)
AIDS
, vol.19
, Issue.1
, pp. 97-99
-
-
Martin, A.M.1
Nolan, D.2
James, I.3
Cameron, P.4
Keller, J.5
Moore, C.6
Phillips, E.7
Christiansen, F.T.8
Mallal, S.9
-
178
-
-
33746767604
-
HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients
-
DOI 10.1097/01.aids.0000238408.82947.09, PII 0000203020060801000007
-
Littera, R.; Carcassi, C.; Masala, A.; Piano, P.; Serra, P.; Ortu, F.; Corso, N.; Casula, B.; La Nasa, G.; Contu, L.; Manconi, P. E. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. Aids, 2006, 20 (12), 1621-1626. (Pubitemid 44162404)
-
(2006)
AIDS
, vol.20
, Issue.12
, pp. 1621-1626
-
-
Littera, R.1
Carcassi, C.2
Masala, A.3
Piano, P.4
Serra, P.5
Ortu, F.6
Corso, N.7
Casula, B.8
La Nasa, G.9
Contu, L.10
Manconi, P.E.11
-
179
-
-
77954378516
-
HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients
-
Likanonsakul, S.; Rattanatham, T.; Feangvad, S.; Uttayamakul, S.; Prasithsirikul, W.; Tunthanathip, P.; Nakayama, E. E.; Shioda, T. HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients. AIDS Res. Ther., 2009, 6, 22.
-
(2009)
AIDS Res. Ther
, vol.6
, pp. 22
-
-
Likanonsakul, S.1
Rattanatham, T.2
Feangvad, S.3
Uttayamakul, S.4
Prasithsirikul, W.5
Tunthanathip, P.6
Nakayama, E.E.7
Shioda, T.8
-
180
-
-
33845945094
-
HLA-Cw8 primarily associated with hypersensitivity to nevirapine [7]
-
DOI 10.1097/QAD.0b013e32801199d9, PII 0000203020070111000029
-
Gatanaga, H.; Yazaki, H.; Tanuma, J.; Honda, M.; Genka, I.; Teruya, K.; Tachikawa, N.; Kikuchi, Y.; Oka, S. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. Aids, 2007, 21 (2), 264-265. (Pubitemid 46036947)
-
(2007)
AIDS
, vol.21
, Issue.2
, pp. 264-265
-
-
Gatanaga, H.1
Yazaki, H.2
Tanuma, J.3
Honda, M.4
Genka, I.5
Teruya, K.6
Tachikawa, N.7
Kikuchi, Y.8
Oka, S.9
-
181
-
-
0035134608
-
Sex differences in nevirapine rash
-
DOI 10.1086/317536
-
Bersoff-Matcha, S. J.; Miller, W. C.; Aberg, J. A.; van Der Horst, C.; Hamrick Jr, H. J.; Powderly, W. G.; Mundy, L. M. Sex differences in nevirapine rash. Clin. Infect. Dis., 2001, 32 (1), 124-129. (Pubitemid 32150957)
-
(2001)
Clinical Infectious Diseases
, vol.32
, Issue.1
, pp. 124-129
-
-
Bersoff-Matcha, S.J.1
Miller, W.C.2
Aberg, J.A.3
Van der Horst, C.4
Hamrick H.J., Jr.5
Powderly, W.G.6
Mundy, L.M.7
-
182
-
-
77952356637
-
Tuberculosis: What we don't know can, and does, hurt us
-
Russell, D. G.; Barry, C. E., 3rd; Flynn, J. L. Tuberculosis: what we don't know can, and does, hurt us. Science, 328 (5980), 852-6.
-
Science
, vol.328
, Issue.5980
, pp. 852-6
-
-
Russell, D.G.1
Barry III, C.E.2
Flynn, L.J.3
-
183
-
-
0035432383
-
Mycobacterium tuberculosis: Here today, and here tomorrow
-
DOI 10.1038/35085034
-
Russell, D. G. Mycobacterium tuberculosis: here today, and here tomorrow. Nat. Rev. Mol. Cell Biol., 2001, 2 (8), 569-577. (Pubitemid 33674008)
-
(2001)
Nature Reviews Molecular Cell Biology
, vol.2
, Issue.8
, pp. 569-577
-
-
Russell, D.G.1
-
184
-
-
0036796798
-
Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment
-
DOI 10.1164/rccm.2108091
-
Sharma, S. K.; Balamurugan, A.; Saha, P. K.; Pandey, R. M.; Mehra, N. K. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am. J.Respir. Crit. Care Med., 2002, 166 (7), 916-919. (Pubitemid 35193218)
-
(2002)
American Journal of Respiratory and Critical Care Medicine
, vol.166
, Issue.7
, pp. 916-919
-
-
Sharma, S.K.1
Balamurugan, A.2
Saha, P.K.3
Pandey, R.M.4
Mehra, N.K.5
-
185
-
-
0032833153
-
Associations of HLA-DRB1, DQB1 and DPB1 alleles with pulmonary tuberculosis in south India
-
DOI 10.1054/tuld.1999.0213
-
Ravikumar, M.; Dheenadhayalan, V.; Rajaram, K.; Lakshmi, S. S.; Kumaran, P. P.; Paramasivan, C. N.; Balakrishnan, K.; Pitchappan, R. M. Associations of HLA-DRB1, DQB1 and DPB1 alleles with pulmonary tuberculosis in south India. Tuber. Lung Dis., 1999, 79 (5), 309-317. (Pubitemid 29479131)
-
(1999)
Tubercle and Lung Disease
, vol.79
, Issue.5
, pp. 309-317
-
-
Ravikumar, M.1
Dheenadhayalan, V.2
Rajaram, K.3
Shanmuga Lakshmi, S.4
Paul Kumaran, P.5
Paramasivan, C.N.6
Balakrishnan, K.7
Pitchappan, R.M.8
-
186
-
-
0029079381
-
Variants of HLA-DR2/DR51 group haplotypes and susceptibility to tuberculoid leprosy and pulmonary tuberculosis in Asian Indians
-
Mehra, N. K.; Rajalingam, R.; Mitra, D. K.; Taneja, V.; Giphart, M. J. Variants of HLA-DR2/DR51 group haplotypes and susceptibility to tuberculoid leprosy and pulmonary tuberculosis in Asian Indians. Int. J. Lepr. Other Mycobact. Dis., 1995, 63 (2), 241-248.
-
(1995)
Int. J. Lepr. Other Mycobact. Dis
, vol.63
, Issue.2
, pp. 241-248
-
-
Mehra, N.K.1
Rajalingam, R.2
Mitra, D.K.3
Taneja, V.4
Giphart, M.J.5
-
187
-
-
3242780716
-
+ T cells in the context of multiple HLA alleles
-
Shams, H.; Klucar, P.; Weis, S. E.; Lalvani, A.; Moonan, P. K.; Safi, H.; Wizel, B.; Ewer, K.; Nepom, G. T.; Lewinsohn, D. M.; Andersen, P.; Barnes, P. F. Characterization of a Mycobacterium tuberculosis peptide that is recognized by human CD4+ and CD8+ T cells in the context of multiple HLA alleles. J. Immunol., 2004, 173 (3), 1966-1977. (Pubitemid 38971633)
-
(2004)
Journal of Immunology
, vol.173
, Issue.3
, pp. 1966-1977
-
-
Shams, H.1
Klucar, P.2
Weis, S.E.3
Lalvani, A.4
Moonan, P.K.5
Safi, H.6
Wizel, B.7
Ewer, K.8
Nepom, G.T.9
Lewinsohn, D.M.10
Andersen, P.11
Barnes, P.F.12
-
188
-
-
70449103049
-
Genetic association studies in drug-induced liver injury
-
Daly, A. K.; Day, C. P. Genetic association studies in drug-induced liver injury. Semin. Liver Dis., 2009, 29 (4), 400-411.
-
(2009)
Semin. Liver Dis
, vol.29
, Issue.4
, pp. 400-411
-
-
Daly, A.K.1
Day, C.P.2
-
189
-
-
78049469917
-
Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury
-
Donaldson, P. T.; Daly, A. K.; Henderson, J.; Graham, J.; Pirmohamed, M.; Bernal, W.; Day, C. P.; Aithal, G. P. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J. Hepatol., 53 (6), 1049-1053.
-
J. Hepatol.
, vol.53
, Issue.6
, pp. 1049-1053
-
-
Donaldson, P.T.1
Daly, A.K.2
Henderson, J.3
Graham, J.4
Pirmohamed, M.5
Bernal, W.6
Day, C.P.7
Aithal, G.P.8
-
190
-
-
0033756344
-
Co-amoxiclav jaundice: Clinical and histological features and HLA class II association
-
O'Donohue, J.; Oien, K. A.; Donaldson, P.; Underhill, J.; Clare, M.; MacSween, R. N.; Mills, P. R. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut, 2000, 47 (5), 717-720.
-
(2000)
Gut
, vol.47
, Issue.5
, pp. 717-720
-
-
O'Donohue, J.1
Oien, K.A.2
Donaldson, P.3
Underhill, J.4
Clare, M.5
MacSween, R.N.6
Mills, P.R.7
-
191
-
-
0032738987
-
HLA association of amoxicillin-clavulanate--induced hepatitis
-
Hautekeete, M. L.; Horsmans, Y.; Van Waeyenberge, C.; Demanet, C.; Henrion, J.; Verbist, L.; Brenard, R.; Sempoux, C.; Michielsen, P. P.; Yap, P. S.; Rahier, J.; Geubel, A. P. HLA association of amoxicillin-clavulanate-- induced hepatitis. Gastroenterology, 1999, 117 (5), 1181-1186.
-
(1999)
Gastroenterology
, vol.117
, Issue.5
, pp. 1181-1186
-
-
Hautekeete, M.L.1
Horsmans, Y.2
Van Waeyenberge, C.3
Demanet, C.4
Henrion, J.5
Verbist, L.6
Brenard, R.7
Sempoux, C.8
Michielsen, P.P.9
Yap, P.S.10
Rahier, J.11
Geubel, A.P.12
-
192
-
-
0031861918
-
Delayed hypersensitivity to aminopenicillins is related to major histocompatibility complex genes
-
Romano, A.; De Santis, A.; Romito, A.; Di Fonso, M.; Venuti, A.; Gasbarrini, G. B.; Manna, R. Delayed hypersensitivity to aminopenicillins is related to major histocompatibility complex genes. Ann. Allergy Asthma Immunol., 1998, 80 (5), 433-437. (Pubitemid 28246777)
-
(1998)
Annals of Allergy, Asthma and Immunology
, vol.80
, Issue.5
, pp. 433-437
-
-
Romano, A.1
De Santis, A.2
Romito, A.3
Di Fonso, M.4
Venuti, A.5
Gasbarrini, G.B.6
Manna, R.7
-
193
-
-
0030902568
-
Stevens-Johnson syndrome induced by methazolamide treatment
-
Shirato, S.; Kagaya, F.; Suzuki, Y.; Joukou, S. Stevens-Johnson syndrome induced by methazolamide treatment. Arch. Ophthalmol., 1997, 115 (4), 550-553. (Pubitemid 27172716)
-
(1997)
Archives of Ophthalmology
, vol.115
, Issue.4
, pp. 550-553
-
-
Shirato, S.1
Kagaya, F.2
Suzuki, Y.3
Jouhou, S.4
-
194
-
-
77952937737
-
HLA-B*5901 is strongly associated with methazolamideinduced Stevens-Johnson syndrome/toxic epidermal necrolysis
-
Kim, S. H.; Kim, M.; Lee, K. W.; Kang, H. R.; Park, H. W.; Jee, Y. K. HLA-B*5901 is strongly associated with methazolamideinduced Stevens-Johnson syndrome/toxic epidermal necrolysis. Pharmacogenomics, 2010, 11 (6), 879-884.
-
(2010)
Pharmacogenomics
, vol.11
, Issue.6
, pp. 879-884
-
-
Kim, S.H.1
Kim, M.2
Lee, K.W.3
Kang, H.R.4
Park, H.W.5
Jee, Y.K.6
-
195
-
-
0030951312
-
Aspirin-induced asthma and HLA-DRB1 and HLA-DPB1 genotypes
-
DOI 10.1111/j.1365-2222.1997.tb00747.x
-
Dekker, J. W.; Nizankowska, E.; Schmitz-Schumann, M.; Pile, K.; Bochenek, G.; Dyczek, A.; Cookson, W. O.; Szczeklik, A. Aspirininduced asthma and HLA-DRB1 and HLA-DPB1 genotypes. Clin. Exp. Allergy, 1997, 27 (5), 574-577. (Pubitemid 27241657)
-
(1997)
Clinical and Experimental Allergy
, vol.27
, Issue.5
, pp. 574-577
-
-
Dekker, J.W.1
Nizankowska, E.2
Schmitz-Schumann, M.3
Pile, K.4
Bochenek, G.5
Dyczek, A.6
Cookson, W.O.C.M.7
Szczeklik, A.8
-
196
-
-
1542407022
-
HLa association in aspirin-intolerant asthma: DPB1*0301 as a strong marker in a Korean population [3]
-
DOI 10.1016/j.jaci.2003.12.012
-
Choi, J. H.; Lee, K. W.; Oh, H. B.; Lee, K. J.; Suh, Y. J.; Park, C. S.; Park, H. S. HLA association in aspirin-intolerant asthma: DPB1*0301 as a strong marker in a Korean population. J. Allergy Clin. Immunol., 2004, 113 (3), 562-564. (Pubitemid 38338966)
-
(2004)
Journal of Allergy and Clinical Immunology
, vol.113
, Issue.3
, pp. 562-564
-
-
Choi, J.H.1
Lee, K.W.2
Oh, H.B.3
Lee, K.J.4
Suh, Y.J.5
Park, C.S.6
Park, H.-S.7
-
197
-
-
17144408997
-
The human leucocyte antigen- DRB1*1302-DQB1*0609- DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria
-
Kim, S. H.; Choi, J. H.; Lee, K. W.; Shin, E. S.; Oh, H. B.; Suh, C. H.; Nahm, D. H.; Park, H. S. The human leucocyte antigen- DRB1*1302- DQB1*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria. Clin. Exp. Allergy, 2005, 35 (3), 339-44.
-
(2005)
Clin. Exp. Allergy
, vol.35
, Issue.3
, pp. 339-44
-
-
Kim, S.H.1
Choi, J.H.2
Lee, K.W.3
Shin, E.S.4
Oh, H.B.5
Suh, C.H.6
Nahm, D.H.7
Park, H.S.8
-
198
-
-
33645309625
-
Cysteinyl leukotriene receptor 1 promoter polymorphism is associated with aspirin-intolerant asthma in males
-
Kim, S. H.; Oh, J. M.; Kim, Y. S.; Palmer, L. J.; Suh, C. H.; Nahm, D. H.; Park, H. S. Cysteinyl leukotriene receptor 1 promoter polymorphism is associated with aspirin-intolerant asthma in males. Clin. Exp. Allergy, 2006, 36 (4), 433-439.
-
(2006)
Clin. Exp. Allergy
, vol.36
, Issue.4
, pp. 433-439
-
-
Kim, S.H.1
Oh, J.M.2
Kim, Y.S.3
Palmer, L.J.4
Suh, C.H.5
Nahm, D.H.6
Park, H.S.7
-
199
-
-
0033219772
-
Leukotriene C4 synthase: A candidate gene for the aspirin-intolerant asthmatic phenotype
-
Penrose, J. F.; Baldasaro, M. H. Leukotriene C4 synthase: a candidate gene for the aspirin-intolerant asthmatic phenotype. Allergy Asthma Proc., 1999, 20 (6), 353-360.
-
(1999)
Allergy Asthma Proc
, vol.20
, Issue.6
, pp. 353-360
-
-
Penrose, J.F.1
Baldasaro, M.H.2
-
200
-
-
33644893345
-
4 synthase allelic variant
-
DOI 10.1111/j.1365-2133.2005.06851.x
-
Mastalerz, L.; Setkowicz, M.; Sanak, M.; Rybarczyk, H.; Szczeklik, A. Familial aggregation of aspirin-induced urticaria and leukotriene C synthase allelic variant. Br. J. Dermatol., 2006, 154 (2), 256-260. (Pubitemid 43382695)
-
(2006)
British Journal of Dermatology
, vol.154
, Issue.2
, pp. 256-260
-
-
Mastalerz, L.1
Setkowicz, M.2
Sanak, M.3
Rybarczyk, H.4
Szczeklik, A.5
-
201
-
-
31544442957
-
Leukotriene-related gene polymorphisms in patients with aspirin-intolerant urticaria and aspirin-intolerant asthma: Differing contributions of ALOX5 polymorphism in Korean population
-
Kim, S. H.; Choi, J. H.; Holloway, J. W.; Suh, C. H.; Nahm, D. H.; Ha, E. H.; Park, C. S.; Park, H. S. Leukotriene-related gene polymorphisms in patients with aspirin-intolerant urticaria and aspirin-intolerant asthma: differing contributions of ALOX5 polymorphism in Korean population. J. Korean Med. Sci., 2005, 20 (6), 926-931. (Pubitemid 43161853)
-
(2005)
Journal of Korean Medical Science
, vol.20
, Issue.6
, pp. 926-931
-
-
Kim, S.-H.1
Choi, J.-H.2
Holloway, J.W.3
Suh, C.-H.4
Nahm, D.-H.5
Ha, E.-H.6
Park, C.-S.7
Park, H.-S.8
-
202
-
-
19944363143
-
2 receptor subtype 2 gene confer susceptibility to aspirin-intolerant asthma: A candidate gene approach
-
DOI 10.1093/hmg/ddh332
-
Jinnai, N.; Sakagami, T.; Sekigawa, T.; Kakihara, M.; Nakajima, T.; Yoshida, K.; Goto, S.; Hasegawa, T.; Koshino, T.; Hasegawa, Y.; Inoue, H.; Suzuki, N.; Sano, Y.; Inoue, I. Polymorphisms in the prostaglandin E2 receptor subtype 2 gene confer susceptibility to aspirin-intolerant asthma: a candidate gene approach. Hum. Mol. Genet., 2004, 13 (24), 3203-3217. (Pubitemid 40045272)
-
(2004)
Human Molecular Genetics
, vol.13
, Issue.24
, pp. 3203-3217
-
-
Jinnai, N.1
Sakagami, T.2
Sekigawa, T.3
Kakihara, M.4
Nakajima, T.5
Yoshida, K.6
Goto, S.7
Hasegawa, T.8
Koshino, T.9
Hasegawa, Y.10
Inoue, H.11
Suzuki, N.12
Sano, Y.13
Inoue, I.14
-
203
-
-
33846850455
-
Significant association of FcεRIα promoter polymorphisms with aspirin-intolerant chronic urticaria
-
DOI 10.1016/j.jaci.2006.10.006, PII S0091674906021208
-
Bae, J. S.; Kim, S. H.; Ye, Y. M.; Yoon, H. J.; Suh, C. H.; Nahm, D. H.; Park, H. S. Significant association of FcepsilonRIalpha promoter polymorphisms with aspirin-intolerant chronic urticaria. J. Allergy Clin. Immunol., 2007, 119 (2), 449-456. (Pubitemid 46204803)
-
(2007)
Journal of Allergy and Clinical Immunology
, vol.119
, Issue.2
, pp. 449-456
-
-
Bae, J.-S.1
Kim, S.-H.2
Ye, Y.-M.3
Yoon, H.J.4
Suh, C.-H.5
Nahm, D.-H.6
Park, H.-S.7
-
204
-
-
47249123298
-
Association of three sets of high-affinity IgE receptor (FcepsilonR1) polymorphisms with aspirin-intolerant asthma
-
Palikhe, N. S.; Kim, S. H.; Cho, B. Y.; Ye, Y. M.; Hur, G. Y.; Park, H. S. Association of three sets of high-affinity IgE receptor (FcepsilonR1) polymorphisms with aspirin-intolerant asthma. Respir. Med., 2008, 102 (8), 1132-1139.
-
(2008)
Respir. Med
, vol.102
, Issue.8
, pp. 1132-1139
-
-
Palikhe, N.S.1
Kim, S.H.2
Cho, B.Y.3
Ye, Y.M.4
Hur, G.Y.5
Park, H.S.6
-
205
-
-
38049115502
-
Association of beta 2-adrenergic receptor polymorphism with the phenotype of aspirin-intolerant acute urticaria
-
Kim, H. A.; Ye, Y. M.; Kim, S. H.; Hur, G. Y.; Park, H. S. Association of beta 2-adrenergic receptor polymorphism with the phenotype of aspirin-intolerant acute urticaria. Yonsei Med. J., 2007, 48 (6), 1079-1081.
-
(2007)
Yonsei Med. J
, vol.48
, Issue.6
, pp. 1079-1081
-
-
Kim, H.A.1
Ye, Y.M.2
Kim, S.H.3
Hur, G.Y.4
Park, H.S.5
-
206
-
-
61349140008
-
Association of TNF-alpha promoter polymorphisms with aspirin-induced urticaria
-
Choi, J. H.; Kim, S. H.; Cho, B. Y.; Lee, S. K.; Suh, C. H.; Park, H. S. Association of TNF-alpha promoter polymorphisms with aspirin-induced urticaria. J. Clin. Pharm. Ther., 2009, 34 (2), 231-238.
-
(2009)
J. Clin. Pharm. Ther
, vol.34
, Issue.2
, pp. 231-238
-
-
Choi, J.H.1
Kim, S.H.2
Cho, B.Y.3
Lee, S.K.4
Suh, C.H.5
Park, H.S.6
-
207
-
-
77954810481
-
Association of SLC6A12 variants with aspirin-intolerant asthma in a Korean population
-
Pasaje, C. F.; Kim, J. H.; Park, B. L.; Cheong, H. S.; Chun, J. Y.; Park, T. J.; Lee, J. S.; Kim, Y.; Bae, J. S.; Park, J. S.; Yoon, S. H.; Uh, S. T.; Choi, J. S.; Kim, Y. H.; Kim, M. K.; Choi, I. S.; Cho, S. H.; Choi, B. W.; Park, C. S.; Shin, H. D. Association of SLC6A12 variants with aspirin-intolerant asthma in a Korean population. Ann. Hum. Genet., 2010, 74 (4), 326-334.
-
(2010)
Ann. Hum. Genet.
, vol.74
, Issue.4
, pp. 326-334
-
-
Pasaje, C.F.1
Kim, J.H.2
Park, B.L.3
Cheong, H.S.4
Chun, J.Y.5
Park, T.J.6
Lee, J.S.7
Kim, Y.8
Bae, J.S.9
Park, J.S.10
Yoon, S.H.11
Uh, S.T.12
Choi, J.S.13
Kim, Y.H.14
Kim, M.K.15
Choi, I.S.16
Cho, S.H.17
Choi, B.W.18
Park, C.S.19
Shin, H.D.20
more..
-
208
-
-
76249091100
-
Genetic variability in CRTH2 polymorphism increases eotaxin-2 levels in patients with aspirin exacerbated respiratory disease
-
Palikhe, N. S.; Kim, S. H.; Cho, B. Y.; Ye, Y. M.; Choi, G. S.; Park, H. S. Genetic variability in CRTH2 polymorphism increases eotaxin-2 levels in patients with aspirin exacerbated respiratory disease. Allergy, 2010, 65 (3), 338-346.
-
(2010)
Allergy
, vol.65
, Issue.3
, pp. 338-346
-
-
Palikhe, N.S.1
Kim, S.H.2
Cho, B.Y.3
Ye, Y.M.4
Choi, G.S.5
Park, H.S.6
-
209
-
-
70449724715
-
Associations of functional NLRP3 polymorphisms with susceptibility to food-induced anaphylaxis and aspirin-induced asthma
-
Hitomi, Y.; Ebisawa, M.; Tomikawa, M.; Imai, T.; Komata, T.; Hirota, T.; Harada, M.; Sakashita, M.; Suzuki, Y.; Shimojo, N.; Kohno, Y.; Fujita, K.; Miyatake, A.; Doi, S.; Enomoto, T.; Taniguchi, M.; Higashi, N.; Nakamura, Y.; Tamari, M. Associations of functional NLRP3 polymorphisms with susceptibility to food-induced anaphylaxis and aspirin-induced asthma. J. Allergy Clin. Immunol., 2009, 124 (4), 779-785 e6.
-
(2009)
J. Allergy Clin. Immunol
, vol.124
, Issue.4
-
-
Hitomi, Y.1
Ebisawa, M.2
Tomikawa, M.3
Imai, T.4
Komata, T.5
Hirota, T.6
Harada, M.7
Sakashita, M.8
Suzuki, Y.9
Shimojo, N.10
Kohno, Y.11
Fujita, K.12
Miyatake, A.13
Doi, S.14
Enomoto, T.15
Taniguchi, M.16
Higashi, N.17
Nakamura, Y.18
Tamari, M.19
-
210
-
-
59349094942
-
Adenosine deaminase and adenosine receptor polymorphisms in aspirin-intolerant asthma
-
Kim, S. H.; Kim, Y. K.; Park, H. W.; Ye, Y. M.; Min, K. U.; Park, H. S. Adenosine deaminase and adenosine receptor polymorphisms in aspirin-intolerant asthma. Respir. Med., 2009, 103 (3), 356-363.
-
(2009)
Respir. Med
, vol.103
, Issue.3
, pp. 356-363
-
-
Kim, S.H.1
Kim, Y.K.2
Park, H.W.3
Ye, Y.M.4
Min, K.U.5
Park, H.S.6
-
211
-
-
54849426412
-
Association of angiotensin I-converting enzyme gene polymorphisms with aspirin intolerance in asthmatics
-
Kim, T. H.; Chang, H. S.; Park, S. M.; Nam, B. Y.; Park, J. S.; Rhim, T.; Park, H. S.; Kim, M. K.; Choi, I. S.; Cho, S. H.; Chung, I. Y.; Park, B. L.; Park, C. S.; Shin, H. D. Association of angiotensin I-converting enzyme gene polymorphisms with aspirin intolerance in asthmatics. Clin. Exp. Allergy, 2008, 38 (11), 1727-1737.
-
(2008)
Clin. Exp. Allergy
, vol.38
, Issue.11
, pp. 1727-1737
-
-
Kim, T.H.1
Chang, H.S.2
Park, S.M.3
Nam, B.Y.4
Park, J.S.5
Rhim, T.6
Park, H.S.7
Kim, M.K.8
Choi, I.S.9
Cho, S.H.10
Chung, I.Y.11
Park, B.L.12
Park, C.S.13
Shin, H.D.14
-
212
-
-
33845900173
-
ADAM33 polymorphisms are associated with aspirin-intolerant asthma in the Japanese population
-
DOI 10.1007/s10038-006-0081-6
-
Sakagami, T.; Jinnai, N.; Nakajima, T.; Sekigawa, T.; Hasegawa, T.; Suzuki, E.; Inoue, I.; Gejyo, F. ADAM33 polymorphisms areassociated with aspirin-intolerant asthma in the Japanese population. J. Hum. Genet., 2007, 52 (1), 66-72. (Pubitemid 46020566)
-
(2007)
Journal of Human Genetics
, vol.52
, Issue.1
, pp. 66-72
-
-
Sakagami, T.1
Jinnai, N.2
Nakajima, T.3
Sekigawa, T.4
Hasegawa, T.5
Suzuki, E.6
Inoue, I.7
Gejyo, F.8
-
213
-
-
20344378203
-
Functional promoter polymorphism in the TBX21 gene associated with aspirin-induced asthma
-
DOI 10.1007/s00439-005-1285-0
-
Akahoshi, M.; Obara, K.; Hirota, T.; Matsuda, A.; Hasegawa, K.; Takahashi, N.; Shimizu, M.; Nakashima, K.; Cheng, L.; Doi, S.; Fujiwara, H.; Miyatake, A.; Fujita, K.; Higashi, N.; Taniguchi, M.; Enomoto, T.; Mao, X. Q.; Nakashima, H.; Adra, C. N.; Nakamura, Y.; Tamari, M.; Shirakawa, T. Functional promoter polymorphism in the TBX21 gene associated with aspirin-induced asthma. Hum. Genet., 2005, 117 (1), 16-26. (Pubitemid 40778778)
-
(2005)
Human Genetics
, vol.117
, Issue.1
, pp. 16-26
-
-
Akahoshi, M.1
Obara, K.2
Hirota, T.3
Matsuda, A.4
Hasegawa, K.5
Takahashi, N.6
Shimizu, M.7
Nakashima, K.8
Cheng, L.9
Doi, S.10
Fujiwara, H.11
Miyatake, A.12
Fujita, K.13
Higashi, N.14
Taniguchi, M.15
Enomoto, T.16
Mao, X.-Q.17
Nakashima, H.18
Adra, C.N.19
Nakamura, Y.20
Tamari, M.21
Shirakawa, T.22
more..
-
214
-
-
77952908167
-
Personalized therapy in pain management: Where do we stand?
-
Stamer, U. M.; Zhang, L.; Stuber, F. Personalized therapy in pain management: where do we stand? Pharmacogenomics, 2010, 11 (6), 843-864.
-
(2010)
Pharmacogenomics
, vol.11
, Issue.6
, pp. 843-864
-
-
Stamer, U.M.1
Zhang, L.2
Stuber, F.3
-
215
-
-
77953517945
-
Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone
-
Gronlund, J.; Saari, T. I.; Hagelberg, N. M.; Neuvonen, P. J.; Olkkola, K. T.; Laine, K. Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br. J. Clin. Pharmacol., 2010, 70 (1), 78-87.
-
(2010)
Br. J. Clin. Pharmacol.
, vol.70
, Issue.1
, pp. 78-87
-
-
Gronlund, J.1
Saari, T.I.2
Hagelberg, N.M.3
Neuvonen, P.J.4
Olkkola, K.T.5
Laine, K.6
-
216
-
-
34547644659
-
Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication
-
DOI 10.1038/sj.tpj.6500406, PII 6500406
-
Kirchheiner, J.; Schmidt, H.; Tzvetkov, M.; Keulen, J. T.; Lotsch, J.; Roots, I.; Brockmoller, J. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J., 2007, 7 (4), 257-265. (Pubitemid 47202488)
-
(2007)
Pharmacogenomics Journal
, vol.7
, Issue.4
, pp. 257-265
-
-
Kirchheiner, J.1
Schmidt, H.2
Tzvetkov, M.3
Keulen, J.-T.4
Lotsch, J.5
Roots, I.6
Brockmoller, J.7
-
217
-
-
27544457008
-
Impact of CYP2C9 genotype on pharmacokinetics: Are all cyclooxygenase inhibitors the same?
-
DOI 10.1124/dmd.105.006452
-
Rodrigues, A. D. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab. Dispos., 2005, 33 (11), 1567-1575. (Pubitemid 41541940)
-
(2005)
Drug Metabolism and Disposition
, vol.33
, Issue.11
, pp. 1567-1575
-
-
Rodrigues, A.D.1
-
218
-
-
43049168656
-
Clinical use and pharmacological properties of selective COX-2 inhibitors
-
Shi, S.; Klotz, U. Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur. J. Clin. Pharmacol., 2008, 64 (3), 233-252.
-
(2008)
Eur. J. Clin. Pharmacol
, vol.64
, Issue.3
, pp. 233-252
-
-
Shi, S.1
Klotz, U.2
-
219
-
-
67649416267
-
Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: Is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?
-
Agundez, J. A.; Garcia-Martin, E.; Martinez, C. Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin. Drug Metab. Toxicol., 2009, 5 (6), 607-620.
-
(2009)
Expert Opin. Drug Metab. Toxicol
, vol.5
, Issue.6
, pp. 607-620
-
-
Agundez, J.A.1
Garcia-Martin, E.2
Martinez, C.3
-
220
-
-
66149123253
-
Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma
-
Chan, A. T.; Zauber, A. G.; Hsu, M.; Breazna, A.; Hunter, D. J.; Rosenstein, R. B.; Eagle, C. J.; Hawk, E. T.; Bertagnolli, M. M. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology, 2009, 136 (7), 2127-2136 e1.
-
(2009)
Gastroenterology
, vol.136
, Issue.7
-
-
Chan, A.T.1
Zauber, A.G.2
Hsu, M.3
Breazna, A.4
Hunter, D.J.5
Rosenstein, R.B.6
Eagle, C.J.7
Hawk, E.T.8
Bertagnolli, M.M.9
-
221
-
-
66449133984
-
HLA and infectious diseases
-
Table of Contents
-
Blackwell, J. M.; Jamieson, S. E.; Burgner, D. HLA and infectious diseases. Clin. Microbiol. Rev., 2009, 22 (2), 370-85, Table of Contents.
-
(2009)
Clin. Microbiol. Rev
, vol.22
, Issue.2
, pp. 370-85
-
-
Blackwell, J.M.1
Jamieson, S.E.2
Burgner, D.3
-
222
-
-
0035653671
-
Genetics of susceptibility to human infectious disease
-
DOI 10.1038/35103577
-
Cooke, G. S.; Hill, A. V. Genetics of susceptibility to human infectious disease. Nat. Rev. Genet., 2001, 2 (12), 967-977. (Pubitemid 33691093)
-
(2001)
Nature Reviews Genetics
, vol.2
, Issue.12
, pp. 967-977
-
-
Cooke, G.S.1
Hill, A.V.S.2
-
224
-
-
79959503826
-
The International HapMap Project
-
The International HapMap Project. Nature, 2003, 426 (6968), 789-796.
-
(2003)
Nature
, vol.426
, Issue.6968
, pp. 789-796
-
-
-
225
-
-
42649145667
-
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
-
Amado, R. G.; Wolf, M.; Peeters, M.; Van Cutsem, E.; Siena, S.; Freeman, D. J.; Juan, T.; Sikorski, R.; Suggs, S.; Radinsky, R.; Patterson, S. D.; Chang, D. D. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol., 2008, 26 (10), 1626-34.
-
(2008)
J. Clin. Oncol
, vol.26
, Issue.10
, pp. 1626-34
-
-
Amado, R.G.1
Wolf, M.2
Peeters, M.3
Van Cutsem, E.4
Siena, S.5
Freeman, D.J.6
Juan, T.7
Sikorski, R.8
Suggs, S.9
Radinsky, R.10
Patterson, S.D.11
Chang, D.D.12
-
226
-
-
77955567583
-
Medications and glucose-6-phosphate dehydrogenase deficiency: An evidence-based review
-
Youngster, I.; Arcavi, L.; Schechmaster, R.; Akayzen, Y.; Popliski, H.; Shimonov, J.; Beig, S.; Berkovitch, M. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug Saf., 2010, 33 (9), 713-726
-
(2010)
Drug Saf.
, vol.33
, Issue.9
, pp. 713-726
-
-
Youngster, I.1
Arcavi, L.2
Schechmaster, R.3
Akayzen, Y.4
Popliski, H.5
Shimonov, J.6
Beig, S.7
Berkovitch, M.8
-
227
-
-
27744516875
-
Diagnosis and management of G6PD deficiency
-
Frank, J. E. Diagnosis and management of G6PD deficiency. Am. Fam. Physician, 2005, 72 (7), 1277-1282. (Pubitemid 43104259)
-
(2005)
American Family Physician
, vol.72
, Issue.7
, pp. 1277-1282
-
-
Frank, J.E.1
-
228
-
-
84905027083
-
-
Accessed December 5 2010
-
Camptosar Full Prescribing Information. http://www.pfizer.com/files/ products/uspi-camptosar.pdf (Accessed December 5, 2010).
-
Camptosar Full Prescribing Information
-
-
-
229
-
-
76749143669
-
CYP2D6 polymorphisms and tamoxifen metabolism: Clinical relevance
-
Higgins, M. J.; Stearns, V. CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr. Oncol. Rep., 2010, 12 (1), 7-15.
-
(2010)
Curr. Oncol. Rep.
, vol.12
, Issue.1
, pp. 7-15
-
-
Higgins, M.J.1
Stearns, V.2
-
230
-
-
77955638355
-
ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA "boxed Warning": A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons
-
Holmes Jr, D. R.; Dehmer, G. J.; Kaul, S.; Leifer, D.; O'Gara, P. T.; Stein, C. M. ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA "Boxed Warning": A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Journal of the American College of Cardiology, 2010, 56 (4), 321-341.
-
(2010)
Journal of the American College of Cardiology
, vol.56
, Issue.4
, pp. 321-341
-
-
Holmes Jr, D.R.1
Dehmer, G.J.2
Kaul, S.3
Leifer, D.4
O'Gara, P.T.5
Stein, C.M.6
|